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Abstract
Background
The development of serological tests for the diagnosis of coeliac disease,
including tests for endomysial and tissue transglutaminase antibodies, has
made population screening for coeliac disease a realistic possibility. Several
serological screening studies from European countries have shown that as
many as 1% of the general population may have undetected coeliac disease.
The implications of this diagnosis are unclear since the only data on the
morbidity and physiological characteristics associated with previously
undetected disease come from small, selected, case series. Most adult
screening studies in the general population have identified only small
numbers (i.e. less than 20 cases) of previously undetected cases and have
therefore been unable to examine these issues through lack of statistical
power.
Clinically diagnosed coeliac disease has traditionally been linked with a
variety of adverse co-morbid conditions including osteoporosis, non-
Hodgkin’s lymphoma and an increased mortality in general. These
conditions are thought to be partly a consequence of the altered nutritional
status associated with the malabsorption that occurs with villous atrophy of
the small bowel in coeliac disease. Although some of the adverse effects of,
for example, vitamin and calcium deficiencies in coeliac disease have
previously been explored whether there may be potentially beneficial effects
of mild malabsorption have not.
There are two main aspects in this thesis. The first is to estimate the
prevalence of undetected coeliac disease in England and explore the
important physiologic correlates of this condition. The second is to examine
the risk of fracture, vascular disease, malignancy and mortality in people with
diagnosed coeliac disease compared to the general population.
Objectives
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1. To estimate the seroprevalence of undetected coeliac disease in
England.
2. To explore the relationship between undetected coeliac disease and
various socio-demographic characteristics and physiological
measures.
3. To quantify the impact of diagnosed coeliac disease (compared to the
general population) on the risk of:
a. Fracture
b. Vascular disease (hypertension, high cholesterol, atrial
fibrillation, myocardial infarction and stroke)
c. Malignancy and mortality
Methods
To examine objectives 1 and 2 I utilised the Cambridge General Practice
Health Study. This study identified individuals aged 45-76 registered with 12
general practices and invited them to complete a health survey, have a bone
density measurement and submit a blood sample between 1990 and 1995.
Serum samples from 7550 participants were tested for antiendomysial
antibody (EMA). Seroprevalence of undetected coeliac disease was defined
by EMA positivity. Differences between EMA positive and negative
participants of various physiological measures and reported characteristics
were estimated using multivariate logistic and linear regression and adjusted
for age, gender, social class and smoking behaviour.
To examine objective 3 I performed a population based cohort study using
the General Practice Research Database to quantify the risk of fracture,
vascular disease, malignancy and mortality in people with coeliac disease
compared to the general population. I identified 4732 people with coeliac
disease and 23620 age and sex matched control subjects. I used Cox
regression to estimate hazard ratios for fracture, myocardial infarction,
stroke, malignancy and mortality, and conditional logistic regression to
estimate the risk of diagnosed hypertension, hypercholesterolaemia and
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atrial fibrillation, in people with coeliac disease compared to the general
population.
Findings
The studies show that undetected coeliac disease is likely to affect about 1%
of the population of England aged 45-76, a figure similar to several other
countries. Those affected more commonly reported “good or excellent
health”, however they do have an increased risk of osteoporosis and mild
anaemia. In contrast they have a favourable cardiovascular risk profile
including lower serum cholesterol and blood pressure.
In people with clinically diagnosed coeliac disease, compared to the general
population, there were small increases in both the absolute and relative
overall fracture incidence with a 2-fold increase in the risk of hip fracture.
Adults with treated coeliac disease did have a favourable vascular disease
risk factor profile but numbers having heart attacks or strokes were modest
and rates of heart attack and stroke were not reduced. There were modest
increases in the overall risks of malignancy and mortality in people with
coeliac disease and most of this excess risk occurred in the first year of
follow up after diagnosis, suggesting ascertainment bias. I found a marked
reduction in the risk of breast and lung cancer in people with coeliac disease
and the mechanism of this merits further attention as it may provide insight
into the aetiology of these common malignancies.
Conclusions
I found that approximately 1% of general adult population of the UK has
undetected coeliac disease. The findings suggest that although coeliac
disease is associated with some adverse conditions; it may also have some
beneficial health effects.
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1 Introduction
The aim of the first study in this thesis is to estimate the prevalence of
previously undetected coeliac disease in England and explore the potential
adverse and beneficial physiologic correlates and socio-demographic
characteristics of those with evidence of the disease compared to those
without. The aim of the subsequent studies is to examine the risk of fracture,
vascular disease, malignancy and mortality in people with clinically
diagnosed coeliac disease compared to the general population.
To understand the rationale for these studies this introduction contains a
brief description of how coeliac disease is defined and diagnosed, and the
clinical manifestation of the disease. This section will also describe what is
already known and not known about its occurrence and the impact of both
previously undetected and clinically diagnosed disease. Finally details of the
objectives of the thesis are given.
1.1 What is coeliac disease?
1.1.1 Historical perspective
Samuel Gee is generally credited with the first accurate clinical description of
coeliac disease when he gave a lecture ‘On the coeliac affection’ at The
Hospital for Sick Children, Great Ormond Street, London, on the 5th of
October 1887. This report was subsequently published in the St
Bartholomew’s Hospital Reports[1]. His summarised description is as
follows:
“There is a kind of chronic indigestion which is met with persons of all ages,
yet is especially apt to affect children between one and five years old. Signs
of the disease are yielded by the faeces; being loose, not formed but not
watery; more bulky than the food taken would seem to account for; pale in
colour, as if devoid of bile; yeasty; frothy, an appearance probably due to
fermentation; stinking, stench often very great, the food having undergone
putrefaction rather than concoction….. The onset is usually gradual, so that
time is hard to fix: sometimes the complaint sets in suddenly, like an
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accidental diarrhoea; but even when this is so, the nature of the disease
soon shows itself….. The course of the disease is always slow, whatever be
its end; whether the patient live or die, he lingers ill for months or years….
But if the patient can be cured at all, it must be by means of diet.”
During the 1920’s attempts were made to “cure” coeliac disease with various
restrictive diets for example the “banana diet” described by Hass[2].
However it was nearly forty years after Gee’s death, in the late 1940’s, that
his suspicions were finally confirmed.
In the 1940’s Williem Karel Dicke, a Dutch physician, noticed that during the
second world war, children with coeliac disease in Holland thrived when
others were starving, only to subsequently relapse when flour was airlifted
into the Netherlands at the end of the war. Furthermore he demonstrated
that malabsorption in coeliac disease was
“elicited or aggravated by certain types of flour, especially wheat and rye
flours”
He came to this conclusion from the clinical observation that there was
variation in the well being of children at different times during their stay in
hospital[3]. Dicke correlated the mood alterations with variations in the stool
weight and frequency. The diet of these children consisted of ‘gruel’. This
was a ‘porridge like’ substance which was common in the Dutch diet at the
time. Dicke discovered that the constituents of the ‘gruel’ varied depending
on the availability of wheat flour. He observed that paediatric patients given
gruel with a rice or potato flour base, appeared to be far ‘happier’ than when
eating the ‘gruel’ based on wheat.
During the 1940’s and 1950’s work was carried out to attempt to identify the
pathological lesion in coeliac disease. Work looking at autopsy specimens
was inconclusive due to post mortem autolysis but suggested small intestinal
abnormalities[4, 5]. Himes and Adlersberg had noted similar changes in
23
jejunal biopsies in life as those observed in post-mortem specimens from
four of their patients[6]. Paulley also noted the same changes in jejunal
mucosal specimens taken at laparotomy[7]. By the mid 1950’s it was well
established that in coeliac disease there was a characteristic change in the
jejunal mucosa of villous atrophy.
In 1953, J. H van de Kamer identified gliadin as the toxic factor in wheat[8]
and that this protein was present in wheat, barley and rye. In 1961 Taylor
discovered circulating antibodies against gliadin in the sera of patients with
coeliac disease[9]. In combination with advances in genetics these two
findings paved the way for the modern understanding of the pathogenesis of
coeliac disease.
1.1.2 Pathogenesis of coeliac disease
The traditional view of the aetio-pathogenesis of coeliac disease is that it
occurs in people who are genetically susceptible and are subsequently
exposed to gluten. Gluten is a heterogeneous mixture of proteins termed
gliadins and glutenins and exposure to gluten is considered to be a
necessary factor in the development of coeliac disease. The mechanisms for
the pathogenesis are discussed below.
1.1.2.1 Genetics
The familial aggregation of coeliac disease shows the importance of genetic
predisposition to the disease. There have been various twin studies that
have estimated monozygotic twin concordance for coeliac disease at about
70%[10]. Some of that concordance has been explained by Human
Leukocyte Antigen (HLA) genetic studies.
Over 97% of people with coeliac disease express the HLA-DQ2 or HLA-DQ8
genes, coding for a class II Major Histocompatibility Complex (MHC)
molecule comprising a DQA1*0501 chain with a DQB1*0201 or DRB1*0301
chain, or DQA1*0301 with a DRB1*0401 or DQB1*0302 chain[11, 12]. As
the function of class II MHC molecules is to present short peptide-antigens
(epitopes) to CD4+ T lymphocytes, this is one of the important pieces of
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evidence in favour of the view that coeliac disease is an aberrant immune
response to gluten.
Further support for this mechanism is that D-gliadin-specific CD4+ T cells
that produce interferon J can be isolated from the intestinal mucosa of
people with untreated coeliac disease. Such T cells are not present in
normal intestine, or in people with coeliac disease on a gluten free diet[13].
In 2000 two independent studies identified immunodominant epitope
peptides from the 57-75 region of D gliadin, which is considered the most
toxic component of gliadin[14, 15]. These experiments, with the addition of a
later report[16], indicated that a large proportion of CD4+ T cells from people
with coeliac disease recognised three overlapping peptides rich in proline
and glutamine (PFPQPQLPY, PQPQLPYPQ, and PYPQPQLPY) which
derive from a region of D gliadin known to be recognised by antibodies found
in people with coeliac disease.
1.1.2.2 Tissue transglutaminase
Tissue transglutaminase (tTG) is an ubiquitous enzyme found in all organs,
including the intestine. It is known to be released upon cellular damage and
to crosslink proteins in order to control tissue damage. This crosslinking
occurs by forming a covalent bond between the sidechain of a glutamine in
one protein with the aminogroup in the sidechain of a lysine in the other
protein[17]. In 1997 Dieterich et al identified tTG as the autoantigen in
coeliac disease[18] and, subsequently, other reports found that increased
levels of tTGA appear to be very specific indicators of the presence of
coeliac disease[19-21]. Each of the three peptide epitopes described above
contains at least one glutamine residue which is a substrate for the
deamidase activity of tTG. Deamidation of these residues is essential for
significant T-cell stimulation, because deamidation exposes negatively
charged aminoacids that are an essential part of the structural motif involved
in binding to the HLA-DQ2 molecule[14-16]. Through these in vitro studies
the concept that tTG plays a critical role in the pathogenesis of coeliac
disease by generating the antigenic epitopes present in D gliadin has
emerged.
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Recent work by Shan et al has shown that digestion of recombinant D2
gliadin with gastric and pancreatic enzymes in vitro produces a highly stable
33-mer peptide that is rich in proline and glutamine and contains all three of
the previously described epitopes[22]. This 33-mer peptide is resistant to in-
vitro digestion with preparations of brush-border enzymes derived from the
small intestine of rats or human beings. In addition this 33-mer peptide has
a selective ability to survive digestion in vivo and may be present in
significant amounts in the normal small intestine. Shan et al also
demonstrated that this product has high specificity for deamidation by tTG
and the resulting products are extremely stimulatory for all the HLA-DQ2
restricted D gliadin specific T cells they examined. The hypothetical scheme
proposed by this work is displayed in Figure 1-1.
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Figure 1-1. Hypothetical scheme for interaction between intestinal processing
proteins and the specific immune system in coeliac disease
Lancet 2003; 361: 1290-1292
Although these findings are supportive of only a few peptides dependent on
tTG dominating the T cell response in coeliac disease work from Koning’s
group is suggestive that epitopes that do not come from this 33-mer peptide
can also stimulate T cells in people with coeliac disease[23]. This perhaps
explains why although highly specific antibody tests for tTG are excellent
predictors of coeliac disease there remains the occasional discrepancy with
the finding of negative antibodies yet an abnormal mucosal lesion.
1.1.2.3 Enteropathy
Marsh classified the small intestinal lesion in people with coeliac disease in
the early 1990’s[24]. He classified various stages of the abnormalities of the
small intestinal mucosa, comprising infiltration of the epithelium with
lymphocytes, hyperplasia of crypts, progressive loss of surface epithelial
cells and villous atrophy. In the Marsh I lesion (lymphocytic enteritis) the
architecture of mucosa appears normal but the mucosal epithelium is
invaded by lymphocytes. Marsh II (lymphocytic enteritis with crypt
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hyperplasia), is characterised by intraepithelial lymphocytosis accompanied
by hyperplasia of the crypts. Marsh III (flat lesion) consists of intraepithelial
lymphocytosis, crypt hyperplasia and villous atrophy. Marsh also described a
type IV lesion (irreversible hypoplastic/atrophic lesion) in which malignant
(lymphomatous) transformation can develop. The observation of increased
numbers of intraepithelial lymphocytes in the small bowel mucosa of people
with coeliac disease has led to work on understanding their role in its
pathogenesis.
1.1.2.4 Intraepithelial lymphocytes
That the increase in intraepithelial lymphocytes is important in the
pathogenesis of coeliac disease was first recognised by Ferguson et al[25].
In particular it has now been recognised that the proportion of J/G
intraepithelial T lymphocytes are increased in people with coeliac disease.
These primitive lymphocytes recognise bacterial nonpeptide antigens and
unprocessed stress-related proteins. Two important stress-induced proteins
that are increased on intestinal epithelial cells by interferon gamma are MICA
and MICB, which resemble major histocompatibility class I genes[26]. MICA
and MICB gene expression is regulated by promotor heat-shock elements
similar to heat-shock protein 70[26]. The receptor (NKG2D) for MICA on
natural killer and J/G T cells has recently been identified[27]. Once activated
J/G T cells secrete chemokines that attract and stimulate cells of the
unspecific (innate) immune response (monocytes/macrophages, neutrophils,
and eosinophils). However, they modulate the antigen-specific immune
response by secreting IL-4, which dampens Th1 activity in favour of Th2
reactivity. Therefore J/G T cells appear to protect the intestinal mucosa from
chronic exposure to damaging agents such as dietary gluten in gluten-
intolerant individuals[17].
1.1.3 Aetiology of coeliac disease
As the concordance between monozygotic twins is at most 70% this
underlines the importance of environmental factors, other than exposure to
gluten, in the development of coeliac disease[10]. I have discussed below
the areas that there is some information available.
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1.1.3.1 Infant feeding practices
It was suggested as early as the 1950’s that breast-fed infants have a later
onset of coeliac disease[28]. In the 1970’s there were reports from England,
Ireland and Scotland that there appeared to be a decline in the incidence of
childhood coeliac disease[29-32]. Changes in infant feeding practices that in
Britain were promoted by new regulations were suggested as a possible
explanation for the decline[33]. Those recommendations advocated breast-
feeding for a minimum of two weeks and preferably for four to six months,
use of infant formulas, avoidance of solids before the age of four months,
and that cereals should not be added to the milk in bottle feeding. There
was speculation that the age at onset in children was increasing yet during at
the same time in Sweden there was no change in incidence with similar
infant feeding recommendations[34].
Two large case-control studies carried out in Italy by Auricchio et al and by
Greco et al examined infant feeding practices in relation to the risk of
developing childhood coeliac disease[35, 36]. Auricchio et al examined
feeding practices in 216 children with coeliac disease and compared them
with those used for their siblings. Siblings eating gluten within the first 2
months of life had a slightly greater risk of developing coeliac disease than
those who were started on gluten from age 3 months. Greco et al similarly
looked at feeding practices in 201 children with coeliac disease and
compared them with 1949 non-coeliac unrelated children. They found a two-
fold increase in risk for developing coeliac disease when gluten had been
introduced before the end of the second month of life although this was
based on parents’ recall so there might have been a reporting bias.
Recently Ivarrson et al investigated infant feeding practices and its impact on
coeliac disease extensively with a series of population-based studies carried
out in Sweden during the 1980’s and 1990’s. In an ecological analysis they
examined national breast feeding practices and infant feeding with respect to
the incidence of childhood coeliac disease[37]. This was in an era of high
breast feeding and late gluten introduction in comparison with the UK. They
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found a rise in incidence during the late 1980’s and early 1990’s, shown in
Figure 1-2, that was preceded by an increase in the amount of gluten
consumed. The national average daily consumption by children below the
age of 2 years of flour from wheat, rye, barley and oats was doubled during
the 1980’s while from 1995 and onwards it declined by one-third.
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Figure 1-2. Incidence of childhood coeliac disease in Sweden
Acta Paediatr 2000; 89: 165-71
Complementing earlier studies this suggested a role for the timing of gluten
introduction in the development of coeliac disease. In addition Ivarrson et al
carried out the largest population based case-control study so far reported
between 1992 and 1995 to examine early life risk factors for the
development of coeliac disease[38]. They included 627 children with
incident coeliac disease and 1254 age, sex and area of residence matched
controls. They found that the risk for development of coeliac disease was
reduced in children below the age of 2 if they were breast fed when gluten
was introduced (adjusted Odds Ratio (OR) 0.59 95% CI 0.42-0.83) and this
relationship was stronger for infants breast-fed beyond the introduction of
gluten (OR 0.36 95% CI 0.26-0.51). They concluded that breast-feeding has
an independent protective effect against the development of coeliac disease
if ongoing when gluten-containing foods are introduced. The interpretation of
these observations was that more gradual introduction of gluten containing
foods, perhaps allowing “tolerance” to develop, influences the development
of coeliac disease.
1.1.3.2 Cigarette smoking
Coeliac disease, like ulcerative colitis, appears to be associated with non-
smoking although it is unclear whether this is a causal association[39-42].
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Although most of these case-control studies show some inverse relation
between current smoking and diagnosed coeliac disease the strength of the
association has varied. This is probably due to the inconsistent reporting of
smoking status among the control populations in comparison with the coeliac
populations where the current smoking proportion was about 40%. In
addition the studies have been small so some random variation must be
expected. There have been no previous reports of “undiagnosed” coeliac
disease and smoking status.
1.1.4 Clinical manifestation
The clinical manifestation of coeliac disease has its onset commonly in either
early childhood, between 9 and 24 months, or in the third or fourth decade of
life[43-47]. In contrast to children where the sex ratio is 1, in general twice
as many women are diagnosed as men as adults. In severe disease a
“classical” syndrome of gastrointestinal malabsorption can occur
characterised by diarrhoea (due to steatorrhoea), weight loss and fatigue.
However, the majority of people diagnosed with coeliac disease nowadays
have a milder constellation of symptoms that include those already
mentioned but may also include a variety of others such as abdominal
discomfort or bloating, indigestion or non-gastrointestinal symptoms[43-47].
Since coeliac disease was first described the clinical manifestation appears
to be changing, with increasing numbers being diagnosed as a result of the
investigation of anaemia and/or non “classical” symptoms[48-52].
Logan et al described the clinical features in adult people with coeliac
disease diagnosed in the Edinburgh and the Lothian areas of Scotland[50].
They compared features at presentation through the four quinquennia
spanning 1960-1979 and found a lower age at diagnosis in women in the
later years, 63% presenting with “typical malabsorption syndrome” in the
1960’s compared with 21% in the 1975-79 and fewer haematological and
biochemical abnormalities in the later periods. Other studies of comparable
design have found similar patterns in adults diagnosed with coeliac
disease[48, 49, 51, 52]. In addition Hin et al recently carried out a case
finding study in primary care in the UK[53]. They tested people in primary
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care who had irritable bowel syndrome, anaemia, malabsorption symptoms
and people with fatigue. They found that people with fatigue and/or having a
past or present diagnosis of microcytic anaemia had the highest prevalence
of previously undetected coeliac disease.
Other haematological features of coeliac disease that have been reported
repeatedly include macrocytic anaemia, hypoproteinaemia, folate deficiency,
hypocalcaemia and abnormal liver function tests particularly
hypertransaminasaemia[50, 54-60].
The data supporting the thought that the clinical manifestation in children
with coeliac disease is also changing with a greater proportion are presenting
with a milder constellation of symptoms similar to the change seen in adults
is less consistent. In a study of the incidence and clinical presentation of
childhood coeliac disease in the Netherlands George et al reported a
decrease in the proportions of children with clinical growth failure in height
and weight at diagnosis between 1975 and 1994. In contrast Greco et al
described features of newly diagnosed cases in their study the Naples area,
Italy between 1973 and 1986[61], and found little change across time. Most
other studies have been too small to make sensible comparisons across time
but the consensus appears to be that childhood coeliac disease diagnosed
more recently may be presenting with a less severe clinical illness[62-65].
One explanation for any changes in presentation could be that the natural
history of the disease is changing, perhaps in response to changing
environmental stimuli like infant feeding practices in children or cigarette
smoking in adults. A more likely explanation is that the ability to make the
diagnosis has improved in both quality and accessibility throughout the last
20 years with the development of both accurate serological markers of the
disease and increasing use of endoscopic biopsy techniques rather than the
traditional Crosby capsule biopsy. Therefore a broader spectrum of people
are being investigated for coeliac disease and consequently being
diagnosed.
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1.1.5 Serological markers
In the 1980’s Chorzelski et al described the production of anti-endomysial
antibodies in people with dermatitis herpetiformis and coeliac disease[66].
Endomysium is a connective tissue protein found in the collagenous matrix
of human and monkey oesophagus. Antibodies to endomysium can be
measured in the serum with the use of indirect immunoflorescence[66]. The
autoantigen recognised by endomysial antibody is tTG which is clearly
important in the pathogenesis of coeliac disease as has been described in
section 1.1.2.2. The Immunoglobulin A antiendomysial antibody (EMA) test
can use either monkey oesophagus or human umbilical cord as substrate
and its diagnostic utility has been shown to be very good, with specificity
estimated at 99% and sensitivity over 90%[67]. In some laboratories
specificity is as high as 99.8% (personal communication, Peter Hill).
However the test is labour intensive and qualitative so requires money, time
and expertise to perform. This has led to the development of enzyme linked
immunoabsorbent assay (ELISA)-based tests for the measurement of IgA
tissue transglutaminase antibody levels that are of comparable sensitivity
and specificity to the EMA test[21, 68-70]. Measuring tTG antibody levels is
quicker, easier and quantitative, so has clear advantages over the EMA
test[44]. Both EMA and tTG have superseded the use of antigliadin
antibodies (AGA) which having been identified as a useful serological marker
in coeliac disease[71] have subsequently been shown to have inferior
diagnostic accuracy[72] with a sensitivity as low as 76%.
Coeliac disease has an association with IgA deficiency so it is possible to
incorrectly label a person as not having coeliac disease in such cases
particularly when using the IgA dependent immunoflorescence EMA test[73].
Recently the improvements in techniques for measuring tTGA have allowed
measurement of low serum IgA using recombinant human tTGA ELISAs[74].
1.1.6 Definition of coeliac disease in this thesis
The current diagnostic criteria for coeliac disease are largely based on the
revised guidelines published by the European Society for Paediatric
Gastroenterology, Hepatology and Nutrition in 1990 that recommended
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reliance on the finding of a structurally abnormal small intestinal intestinal
mucosa as described in section 1.1.2.3, followed by a clear clinical or
histological remission on a gluten free diet[75]. Serological markers are used
to either add additional evidence in favour of the diagnosis and/or to initially
identify people who may have the condition.
The definition of coeliac disease in this thesis varies according to
epidemiological need. The underlying assumption I have used is that coeliac
disease is a life-long condition consequent upon genetic predisposition and
exposure to gluten in the diet. In the study of prevalence of undetected
coeliac disease I rely solely on serological evidence as a marker of
“undetected coeliac disease”, whereas in the studies of health impact of
clinically diagnosed coeliac disease I rely on the premise that those people
who have such a diagnosis recorded by their general practitioner were given
it correctly. The merits and limitations of both definitions are discussed in
detail with respect to the findings of the studies.
1.1.7 Occurrence
1.1.7.1 Prevalence
1.1.7.1.1 Undetected coeliac disease
Several serological screening studies from Europe, South America,
Australasia and the United States of America have shown that approximately
0.5-1% of these populations may have undetected coeliac disease[76-84].
There is however some variation in the prevalence estimates in screening
studies ranging from about 1 in 20 to 1 in 700. To discuss the methodology
and findings I have split the studies into three groups: adult blood donor
studies (Table 1-1), general population studies in children (Table 1-2) and
general population studies in adults (Table 1-3). From the available data I
have calculated the proportion of cases identified and the 95% Confidence
Intervals (95% CI) using the binomial distribution. To assess whether the
estimates vary by chance I carried out F2 tests on the data in each of the
tables.
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Adult blood donor studies
In all of the studies in Table 1-1 specimens for serological analysis were
acquired from blood transfusion services in the country of origin. In three of
the five their screening strategy used antiendomysial antibodies (EMA) as
their test of prevalence[85-87], whereas in the remaining two studies
antigiadin antibodies (AGA) were used first with EMA used in those who
were positive.
Four of the five studies reported the age and sex distribution of their sample
population. The mean age of participants varied from 31 to 41 years and in
these studies the proportion of male participants ranged from 52% to 88%.
Apart from the American study all the rest confirmed coeliac disease by
assessing the small intestinal mucosa for histological abnormalities
consistent with the disease. As can be seen in Table 1-1 the estimates of
prevalence show little variation. When tested for variation using a F2 test
there was no greater variation than expected by chance (Pearson F2=2.1
p=0.7).
I believe that this is unsurprising as the study methodologies were similar
and the study populations are likely to be not too heterogeneous being all
blood donors. These estimates show in general lower prevalence than the
general population estimates shown in Table 1-2 and Table 1-3. This is also
unsurprising as most transfusion services have some form of haemoglobin
related entry criteria which are likely to have excluded some people with
coeliac disease on the grounds of anaemia[50].
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Table 1-1. Estimates of prevalence of coeliac disease from adult blood donor screening studies
Area Mean or
median* age
Proportion of
males
Cases Number
screened
Prevalence Proportion
identified
95% CI of
proportion
Year
published
Reference
Sweden 41 65% 4 1970 1 in 492 0.20 0.06-0.52 1999 [88]
Italy 35 75% 10 4000 1 in 400 0.25 0.12-0.46 1999 [85]
Holland Not reported Not reported 3 1000 1 in 330 0.30 0.06-0.87 1999 [86]
Brazil 33* 87% 3 2045 1 in 681 0.15 0.03-0.43 2000 [89]
USA 39 52% 8 2000 1 in 250 0.40 0.17-0.79 2001 [87]
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General population based studies in children
In the five studies in Table 1-2 general population based samples of children
were recruited for screening for coeliac disease. In the Italian school district
of Pesaro-Urbino Catassi et al recruited 66% of eligible school children aged
11-15 years between 1992 and 1993[90]. They used a negative AGA test to
rule out coeliac disease and for all those positive tested them for EMA and,
where they agreed, small bowel biopsy. Mean age was 12.8 years and 49%
were male. In Sardinia, Italy Meloni et al carried out a similar study of 1607
school children during 1993-1994[91]. They did not report the overall
number eligible for recruitment but the age range of participants was 6-14
years and 53% were male. In this study they used AGA to rule out coeliac
disease but in addition tested 53 AGA negative participants for EMA as a
control. Of these 53, one was positive but subsequently refused small
intestinal biopsy. Those positive for AGA were offered small intestinal
biopsy. Overall they found a prevalence of 1 in 93 children with previously
undetected coeliac disease.
This latter finding has been replicated in two further large studies, one from
the UK and one from Finland. The UK study used blood stored anonymously
for the Avon Longitudinal Study of Parents and Children which is a
population based birth cohort study established in 1990[92]. This study
tested 5470 children aged 7.5 years for tTGA and then EMA with 54 found to
be positive for the latter test. Maki et al tested 3654 students aged between
7 and 16 years in Finland. They tested all subjects for both tTGA and EMA,
50% of who were male, and offered small intestinal biopsy to those who were
positive. Both these studies found a prevalence of about 1 in 100.
The study of Saharawi children carried out by Catassi et al in 1998
surprisingly showed the highest prevalence of all screening studies[93]. In
this study 989 children (mean age 7.4 years, males 47%) of Saharawi
descent who were now living in an Algeria province as refugees were tested
for EMA and a sample of positive participants had their small intestinal
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mucosa biopsied. They found that 5% of the children were positive for EMA.
Reasons for this high prevalence, which is markedly different to all the other
general population estimates, are unclear. The authors speculated that
coeliac disease might confer some “protection” against intestinal infections or
parasites.
If all studies in Table 1-2 are included in the F2 analysis then there is
variation greater than expected by chance (Pearson F2=160.4 p<0.01) yet if
the three most recent European studies are compared the findings did not
differ.
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Table 1-2. Estimates of prevalence of coeliac disease from general population based screening studies in children
Area Mean age or
age range*
Proportion
of males
Cases Number screened Prevalence Proportion
identified
95% CI of
proportion
Year
published
Reference
Italy 13 50% 11 3351 1 in 305 0.33 0.16-0.59 1994 [90]
Italy 6-14* 53% 17 1607 1 in 93 1.06 0.62-1.69 1999 [91]
Sahara 7.4 53% 56 989 1 in 18 5.66 4.31-7.29 1999 [93]
Finland 7-16* Not
reported
37 3654 1 in 99 1.01 0.71-1.39 2003 [94]
Bristol,
UK
7.5 Not
reported
54 5470 1 in 100 0.99 0.74-1.29 2004 [92]
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General population based studies in adults
Table 1-3 shows adult general population based screening studies for
coeliac disease. Three of these studies used populations recruited for the
World Health Organisation MONICA project (Monitoring of trends and
determinants in Cardiovascular disease)[76, 77, 82]. Samples of each
Country’s general population were randomly selected from population
registers stratified by age and sex. They were similar in design although one
of the studies has been reported only as an abstract to date so the details
available are not comprehensive. All three studies used a combination of
AGA and EMA to identify people with previously undetected coeliac disease
but not all had had small intestinal biopsy at the time of publication.
All the other studies except the Argentinean study used EMA as the main
test for identifying people with undetected coeliac disease. In general the
study populations were selected randomly with age and sex stratification yet
the summary measures of the age distributions shown in Table 1-3 are
suggestive of some variation. When I analysed the data in Table 1-3 using a
F2 test there was greater variation in the estimates than expected by chance
(Pearson F2 =16.4 p<0.05).
None of the studies provide age and sex standardised estimates of
prevalence so it is difficult to assess whether differences in the estimates are
due to differences in the demographics of the populations studied. There did
not seem to be a consistent pattern either geographical or methodologically
in the studies to explain this variation but putative reasons for the observed
differences could be related to infant feeding practices, cigarette smoking, or
other as yet unidentified important environmental factors.
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Table 1-3. Estimates of prevalence of coeliac disease from population based screening studies in adults
Area Mean age
and/or age
range*
Proportion
of males
Cases Number
screened
Prevalence Proportion
identified
95% CI of
proportion
Year
published
Reference
Ireland 15-65 Not
reported
15 1823 1 in 122 0.82 0.46-1.35 1997 [77]
Italy 44, 20-89 47% 4 2237 1 in 555 0.18 0.05-0.46 1997 [95]
Sweden 50, 25-74* 50% 10 1894 1 in 188 0.53 0.25-0.97 1999 [76]
Spain 45, 2-89* 45% 3 1170 1 in 389 0.26 0.05-0.75 2000 [79]
France 35-64* Not
reported
3 1163 1 in 388 0.26 0.05-0.75 2000 [82]
Italy 12-65* 48% 17 3483 1 in 204 0.49 0.28-0.78 2001 [80]
Argentina Median 29,
16-79*
50% 12 2000 1 in 167 0.60 0.31-1.05 2001 [84]
Australia 20-79* 50% 7 3011 1 in 430 0.23 0.09-0.48 2001 [83]
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1.1.7.1.2 Clinically diagnosed disease
Estimates of the prevalence of clinically diagnosed coeliac disease ranging
from about 0.05% to 0.27% are available from several other studies[32, 96-
98]. From data in Derby, UK the estimated prevalence of clinically
diagnosed coeliac disease at the end of 1999 was 1 in 714 or 0.14%
(unpublished data). These estimates probably vary due to differences in
case ascertainment in the different areas reflecting some local interest in
coeliac disease.
1.1.7.2 Incidence
1.1.7.2.1 Childhood coeliac disease
Studies of the incidence of childhood coeliac disease in the UK have shown
a general decline in incidence during the mid 1970’s[29-31]. Other countries,
apart from Sweden, have also showed some evidence of a decline[99, 100].
Most of these studies calculated cumulative incidence as the number of
cases identified by year of birth with the denominator being the total births in
the same year. Other studies from that era used hospital admission data,
self- or parent-reported coeliac disease, and membership of national coeliac
societies all of which are liable to variation by ascertainment[101, 102]. The
explanation for this decline may be related to infant feeding practices as
discussed in section 1.1.3.1. Another explanation may be that the age of
diagnosis of coeliac disease rose during this period however there is little
direct evidence of this in the available data.
More recently some studies have suggested that the incidence of childhood
coeliac disease may be rising during the late 1980’s and 1990’s. The data
from Sweden reported by Ivarsson et al related the rise in childhood coeliac
disease seen to infant feeding practices[37]. In a recent population based
study from the Netherlands however there was no such change in infant
feeding practices during the period studied yet an increase in incidence[63].
In the South Glamorgan, UK incidence rates in children appear stable but the
population covered in this study was not large enough to allow valid
comparisons over time[48].
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1.1.7.2.2 Adult coeliac disease
The rate of diagnosis of adult coeliac disease has risen dramatically in most
areas of the world where there is data available to monitor such trends[48,
96-98]. Although rate of diagnosis does not completely represent incidence,
as diagnostic mechanisms have changed with the advent of serological
markers, certainly coeliac disease is being more commonly recognised. The
estimated annual rate of diagnoses from various areas is shown in Figure
1-3. An interest in coeliac disease research in some centres probably
combined with an active “case-finding” strategy may explain the variation
apparent in these figures. In combination with the diagnosed disease
prevalence estimates they though do indicate the substantial gap between
the number of people with clinically diagnosed and undetected disease. The
ratio of “undetected” disease to symptomatic disease is probably therefore
around 8:1.
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Figure 1-3. Estimated annual rate of diagnosis (by quinquennia) of coeliac
disease from various geographical areas
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1.2 What is the impact of previously undetected coeliac disease?
The implications of recognising undetected coeliac disease at a general
population level are unclear since the few reported data on the morbidity and
physiological characteristics associated with previously undetected disease
are from small, selected, case series. No studies so far have been able to
look at a wide variety of socio-demographic and physiological factors with
respect to undiagnosed coeliac disease as most adult screening studies in
the general population have identified only small numbers of previously
undiagnosed cases and have therefore been unable to examine any
associations in comparison with the general population[103-105].
Of the studies that have looked at the differences between clinically
diagnosed disease and “screening” or previously undetected disease, most
have focussed on bone mineral density and anthropometric measurements.
The findings, although not consistent, suggest that people with undetected
coeliac disease have a slight tendency towards low bone density and
measurements in keeping with mildly subnormal nutritional status[103-105].
There have been no studies large enough to look at relationships between
undetected coeliac disease and important co-morbidity such as
cardiovascular disease or stroke nor have they been able to examine
mortality or malignancy in such a group.
46
1.3 What is the impact of clinically diagnosed coeliac disease?
1.3.1 Osteoporosis and fracture
The clearly documented association between osteoporosis and coeliac
disease may be due to a combination of malabsorption, secondary
hyperparathyroidism and abnormal calcium homeostasis[106-108]. As a
consequence of osteoporosis there may be an increased risk of fracture in
people with coeliac disease. Due to this perceived increase in fracture risk,
some groups have recommended screening and surveillance of people with
coeliac disease for decreased bone mineral density in order to implement
treatment with bisphosphonates or hormone replacement therapy[43, 109,
110]. However, precise estimates of the excess fracture risk experienced by
people with coeliac disease in comparison with the general population are
not available, mainly because previous studies have been limited by their
size, selected nature and inability to adjust for potential confounders[111-
114]. Vasquez et al compared the fracture experience of 165 patients
(median age 40 years) with that of controls with functional gastrointestinal
disorders and found a three-fold increase in overall fracture risk (Odds ratio
OR 3.5 95% CI 1.8-7.2) based on 25% of patients reporting fractures and
only 8% of controls[112]. A subsequent study from the same group found
that the increase in fracture experience was confined to people with coeliac
disease presenting with “classical malabsorption” (OR 5.2 95% CI 2.8-9.8)
compared to age-sex matched controls[115]. Fickling et al reported a
“relative risk” of fracture of 7 based on a survey of 75 patients with a mean
age of 52 years and age and sex matched controls selected from patients
who had attended for bone densitometry[114]. While 21% of their patients
with coeliac disease reported a past fracture, only two (3%) of the controls
did.
In contrast both Vestergaard et al, in a database study of 1021 hospital
diagnosed subjects with coeliac disease, and Thomason et al, using a
mailed questionnaire survey of 244 cases, found no increase in the overall
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fracture risk compared to the general population but with wide confidence
limits[111, 113].
1.3.2 Vascular disease
Whether coeliac disease might afford protection from certain diseases, due
partly to chronic malabsorption, needs consideration particularly since any
protection might be reduced by treatment with a gluten free diet. This
possibility was first raised by Whorwell et al who found a 40% reduction in
ischaemic heart disease mortality in coeliac disease[116]. The possibility
exists that low-grade chronic malabsorption, although leading to some
vitamin and mineral deficiencies, may confer benefit through fat
malabsorption or possibly altered salt homeostasis leading to, for example,
lower serum cholesterol or lower blood pressure. Only one previous study
has looked at serum cholesterol in diagnosed coeliac disease and concluded
that “cholesterol malabsorption” led to the relative hypocholesteroaemia they
found[117].
1.3.3 Malignancy and mortality
The early studies of the risk of malignancy and mortality in people with
coeliac disease suggested a 2-fold increase in mortality rate, and greatly
increased risks of lymphoproliferative malignancies. Most studies were small
or not population-based, and their findings probably do not reflect the risks in
contemporary coeliac disease[118-122]. More recent data from Sweden
based on cases from their hospital inpatient register have suggested more
modest increases in the risks but still found that people with coeliac disease
were at excess risk of certain malignancies and death[123, 124]. Although
large and population-based these studies were dependent on hospital
admission of the index case for ascertainment. It is possible, therefore, that
this may have led to an overestimate of the risks. The majority of other
studies have found overall increased risks for malignancy or mortality of 2-
fold or greater[118, 119, 121, 122]. These studies have been in cohorts of
people with coeliac disease diagnosed and followed up some time ago, or
from specialist referral centres. Generally they have been limited by not
being population based or too small to provide robust estimates.
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In contrast to the overall increased risks of mortality and malignancy two
studies have suggested a decrease in the risk of breast cancer in people with
coeliac disease, the reasons for which are not clear[121, 124]. A lack of
breast cancer in people with coeliac disease was observed in both the
Lothian and Swedish cohorts yet the former study was too small to be sure
of the association and Askling et al were concerned that, among many
comparisons, it may have been a chance finding.
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1.4 Justification for the studies in this thesis
The development of accurate serological testing for coeliac disease has led
some to debate the limitations and merits of population screening and/or
screening “at risk groups” for the disease[125-128]. Indeed, coeliac disease
fulfils several of the requirements of a condition suitable for population
screening, according to the World Health Organisation criteria namely it
appears to be relatively common, a suitable screening test is available and
an effective treatment exists. However there are still areas where there is an
absence of good information, in particular, about the natural history of the
disease and whether by early detection (and treatment) of coeliac disease
there can be an improvement in health at either a population or individual
level. The possibility of doing harm by identifying previously unknown coeliac
disease, and changing its physiological effects through treatment, is rarely
discussed.
By more clearly understanding the physiological and socio-demographic
associations of previously undetected disease and how common it is I might
be able to add to this debate. The morbidity and mortality associated with
clinically diagnosed coeliac disease are also not well quantified. Through
understanding the impact of clinically diagnosed coeliac disease on health I
may be able to provide information for people with the disease, and in
addition possibly make inferences about the impact of previously undetected
disease.
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1.5 Objectives
The overall aim of this thesis is to achieve the following objectives. The
section number in which each objective is addressed is given below.
1. To estimate the seroprevalence of undetected coeliac disease in England
(section 2)
2. To explore the relationship between undetected coeliac disease and
various socio-demographic characteristics and physiological measures
(section 2)
3. To quantify the impact of diagnosed coeliac disease compared to the
general population on the risk of:
a. Fracture (section 4)
b. Vascular disease – hypertension, high cholesterol diagnosis,
atrial fibrillation, myocardial infarction and stroke (section 5)
c. Malignancy (section 6)
d. Mortality (section 6)
The overall methods for objectives 1 and 2 are described in section 2 and for
objective 3 are described in section 3.
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2 Seroprevalence, correlates and characteristics of previously
undetected coeliac disease in England
2.1 Introduction
This section will describe a general population-based study of the prevalence
of undetected coeliac disease. The section also describes the physiological
and socio-demographic associations with undetected coeliac disease.
2.2 Methods
2.2.1 Participants
The Cambridge General Practice Health Study identified individuals aged 45-
76 registered with 12 general practices (a list of registered names were held
by the Cambridgeshire Family Practitioner Committee) and invited them for a
health survey and bone density measurement between 1990 and 1995.[129-
131] All those consenting completed a health and lifestyle questionnaire that
included questions on occupation, past medical history, cigarette smoking
habit and whether they rated their general health as “excellent, good,
moderate or poor”. They were also asked about known illnesses using the
question: “Have you ever been diagnosed by a doctor as suffering from any
of the following conditions? (please tick yes or no)” followed by a list of
specific conditions. Self reported cardiovascular disease was defined as a
positive answer for any one or more of the conditions: heart attack, angina,
high blood pressure and stroke. Participants then attended for a physical
examination including measurement of blood pressure and bone mineral
density (BMD), the latter measured at the total hip, and total spine by dual
energy X-ray absorptiometry, using the Hologic QDR-1000 densitometer
(Hologic, Waltham, MA). Blood samples were taken by venepuncture and
serum lipids were measured in fresh samples in the Hinchingbrooke Hospital
biochemistry laboratory. All participants have been flagged at the Office for
National Statistics for mortality and have been followed up to the end of May
2001. Death certificates were coded according to the 9th Revision of the
International Classification of Diseases.[132] I was unable to gain access to
participants for the purposes of duodenal biopsy.
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2.2.2 Ethical approval
The study was approved by the Cambridge District Local Research Ethics
Committee.
2.2.3 Serology
Serum samples have been stored at -15 degrees Celcius or below and had
been thawed a maximum of three times previously. The sera were
investigated for the presence of IgA class antiendomysial antibody (EMA)
using indirect immunofluorescence on commercial monkey oesophagus
sections (The Binding Site, Birmingham, UK), using a 1 in 10 serum dilution.
A positive control was included with every batch of 40 samples. Samples
positive for EMA were further tested for human anti-tissue transglutaminase
antibody (tTGA), using a commercially available quantitative ELISA kit
(Celikey£, Pharmacia diagnostics AB, Freiburg, Germany). Results of <3
U/mL were considered to be negative based on the experience in the
laboratory at the Derbyshire Royal Infirmary. Total serum IgA was measured
in all sera and considered results of <0.05g/L to indicate selective IgA
deficiency.
2.2.4 Definitions
2.2.4.1 Coeliac disease
I defined undetected coeliac disease as those participants without self
reported coeliac disease that had a positve EMA test. Definitions for the
presence or absence of coeliac disease in participants follow:
x Participants with probable coeliac disease (treated): those who
reported taking a gluten free diet and having a medical condition
coded as malabsorption (including coeliac disease) and who were
EMA negative
x Participants with probable coeliac disease (untreated): those who
reported having a medical condition coded as malabsorption
(including coeliac disease) but did not report taking a gluten free diet,
and who were EMA positive
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x Participants with possible coeliac disease: those who reported taking
a gluten free diet but did not report having a medical condition coded
as malabsorption (including coeliac disease) and who were EMA
negative
x Participants not previously diagnosed with coeliac disease: those that
did not report being on a gluten free diet, or having any other medical
condition coded as malabsorption (including coeliac disease). This
group was further subdivided into those who were EMA negative (no
evidence of coeliac disease) and those who were EMA positive
(undetected coeliac disease). The latter group was further subdivided
on the basis of tTGA results
2.2.4.2 Socio-economic status
Socio-economic status was coded from the highest reported occupation of
the participant or their spouse using the registrar general’s classification and
grouped as: professional and managerial, lower professional – group 1, non-
manual skilled, manual skilled – group 2, partly skilled, unskilled, armed
forces, inadequately described, housewife/homemaker, retired – group 3.
2.2.4.3 Osteoporosis
Participants were defined as having osteoporosis if their BMD measurement
was 2.5 standard deviations (SD) or more below the young adult mean.
2.2.4.4 Anaemia
Participants were categorised into those who were anaemic and those who
were not (anaemia = haemoglobin in men<13 g/dL and in women<11.5 g/dL)
2.3 Statistical analysis
Fisher’s Exact test, F2 tests and F2 tests for trend were used to examine the
association between smoking, socio-demographic and other binary variables
and EMA positivity. Comparisons between EMA positive and EMA negative
participants with regard to laboratory, anthropometric and bone density
variables were examined using independent samples t-tests. Multivariate
54
analyses were performed to adjust for age, gender, smoking, social class
and other potential confounders using logistic regression for binary and
multiple linear regression for continuous dependent variables. We tested
biologically plausible interactions, particularly those with gender, by adding
multiplicative interaction terms to the multivariate linear regression model.
Where data on confounders was missing these data were modelled as
separate categories to ensure nested models contained the same number of
participants. All significance tests were two-sided. The assumptions of
multiple linear regression were checked by examining histograms of
residuals and normal probability plots.
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2.4 Results
A total of 20,314 individuals were mailed an invitation to participate. Of those
mailed 8515 (42%) agreed to participate. Of those who participated, there
were 7550 (89%) with blood specimens available for serological testing. Of
the 7440 EMA negative participants, 9 had evidence of selective IgA
deficiency. An overview of the number of participants in the study is shown
in Figure 2-1.
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Figure 2-1. Overview of study participants
8515 participants with
blood samples
7550 participants whose
samples were sent to Derby
965 participants whose
samples were not
available for dispatch to
Derby
7527 participants not
previously diagnosed with
coeliac disease
3 participants
with probable
coeliac disease
(treated)
1 participant
with probable
coeliac disease
(untreated)
19 participants
with possible
coeliac disease
77 participants EMA
positive and tTGA
abnormal
(t3 U/mL)
87 participants
EMA positive with
undetected coeliac
disease
7440
participants
EMA negative
10 participants
EMA positive and
tTGA normal
(<3 U/mL)
Included Excluded
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There were a total of 7527 participants not previously diagnosed with coeliac
disease included in the analyses. The mean age of these participants was
59 years (SD 8.9) and 4444 (59%) were female. Estimates of the
seroprevalence of undetected coeliac disease are shown in Table 2-1. The
overall seroprevalence of undetected coeliac disease was 1.2% (95% CI 0.9-
1.4) based on EMA positivity alone (n=87) and 1.0% (95% CI 0.8-1.3) based
on EMA positive and abnormal tTGA results (n=77). Seroprevalence
showed some variation by age and gender.
58
Table 2-1. Seroprevalence of undetected coeliac disease using antiendomysial antibody (EMA) and human anti-tissue
transglutaminase (tTGA) tests by age and gender
<55 years 55–64 years >=65 years Total
M F M F M F M F
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
EMA +ve 12(1.1) 25 (1.4) 12(1.3) 18(1.3) 6 (0.6) 14(1.1) 30(1.0) 57(1.3)
EMA +ve &
tTGA +ve
10(0.9) 20(1.1) 11(1.2) 16(1.2) 6(0.6) 14(1.1) 27(0.9) 50(1.1)
Total 1087 1744 925 1384 1071 1316 3083 4444
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Table 2-2 shows the distribution of tTGA results in the EMA positive
participants considered to have undetected coeliac disease. Seventy five
percent of the EMA positive participants’ tTGA results were unequivocally
abnormal (>6 U/mL).
Table 2-2. tTGA results in the EMA positive participants considered to have
undetected coeliac disease
tTGA EMA +ve
Category n %
<3 10 11.5
3-6 11 12.6
>6-10 8 9.2
>10-20 23 26.4
>20 35 40.2
Total 87 100
EMA positive participants were less likely to have reported being ex or
current smokers (Table 2-3), compared to EMA negative participants, and
also showed a trend towards higher social class, although this was not
significant at the 5% level (F2 for trend, p=0.08). Mutual adjustment and
adjusting for age and gender did not appreciably change these associations.
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Table 2-3. Sociodemographic and smoking characteristics of study
participants by antiendomysial antibody (EMA) result
EMA-ve EMA+ve Odds ratio for positive EMA test (95% CI)
n (%) n (%) Univariate Multivariate*
Gender
Female 4387(59.0) 57(65.5) 1 1
Male 3053(41.0) 30(35.5) 0.76(0.49-1.18) 0.83(0.52-1.32)
Age group
< 55 years 2794(37.6) 37(42.5) 1 1
55-64 years 2280(30.6) 30(34.5) 0.99(0.61-1.61) 1.01(0.62-1.65)
>= 65 years 2366(31.8) 20(23.0) 0.64(0.37-1.10) 0.67(0.38-1.16)
Social class group
Professional 3573(48.0) 49(56.3) 1 1
Skilled 3011(40.5) 32(34.5) 0.78(0.50-1.21) 0.82(0.52-1.29)
Partly skilled and
unskilled
649(8.7) 4(4.6) 0.45(0.16-1.25) 0.51(0.18-1.43)
Missing values 207(2.8) 2(2.3)
Smoking status
Never 3371(45.3) 52(59.8) 1 1
Ex 3024(40.6) 30(34.5) 0.64(0.41-1.01) 0.71(0.45-1.14)
Current 958(12.9) 5(5.7) 0.34(0.14-0.85) 0.36(0.14-0.90)
Missing values 87(1.2) 0(0)
* Mutually adjusted for other variables in the table
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In the univariate analyses EMA positive participants had lower mean
haemoglobin, total protein, corrected calcium, cholesterol, low density
lipoprotein, triglyceride, diastolic blood pressure and weight (all p<0.05,
Table 2-4). Mean BMI, hip and spine BMD, systolic blood pressure, mean
cell volume and albumin were all slightly lower in participants with undetected
coeliac disease, but these differences were not significant at the 5% level.
Both alanine aminotransferase and platelet count were higher among EMA
positive participants. After adjustment for age, gender, smoking status and
social class the differences in weight and diastolic blood pressure were not
significant at the 5% level.
In the multivariate analyses undetected coeliac disease was associated with
a reduction of 0.5 mmol/L (95% CI 0.3 to 0.8 mmol/L) in cholesterol and 0.3
g/dL (95% CI 0.1 to 0.5 g/dL) in haemoglobin. For BMD the mean difference
at the hip was -0.02 g/cm2 (95% CI -0.05 to +0.02 g/cm2) and at the spine
0.03 g/cm2 (95% CI -0.07 to +0.02 g/cm2). There were significant
interactions between the effects of EMA result and gender upon corrected
calcium (p=0.001) and high density lipoprotein (p=0.001) only. Mean
corrected calcium was reduced in EMA positive participants among women
only (–0.05 mmol/L 95% CI –0.07 to –0.02 mmol/L) and there was a similar
effect for high density lipoprotein (–0.14 mmol/L 95% CI –0.24 to –0.04
mmol/L).
There were no statistically significant associations between undetected
coeliac disease and reported morbidity but reporting having high blood
pressure, high cholesterol, angina or heart attack, diabetes or
bronchitis/emphysema all appeared to be less common in those who were
EMA positive (Table 2-5).
62
Table 2-4. Distribution of selected physiologic variables by antiendomysial antibody (EMA) test result
Dependent variable EMA-ve EMA+ve Mean difference (standard error)
Mean (n) Mean (n) Univariate Multivariate§
Haemoglobin (g/dL) 13.7(7425) 13.3(87) -0.4(0.2)** -0.3(0.1)**
Mean cell volume (fl) 89.4(7423) 88.9(87) -0.6(0.6) -0.4(0.5)
Platelet count (x109/L) 260.9(7406) 279.7(87) 18.8(9.2)* 18.2(6.5)**
Total protein (g/L) 71.1(7436) 70.2(87) -0.9(0.5)* -1.0(0.5)*
Albumin (g/L) 42.0(7438) 42.0(87) -0.1(0.4) -0.3(0.4)
Alkaline phosphatase (IU/L) f 161.9(7438) 163.6(87) 1.0(0.9-1.1) 1.0(1.0-1.1)
Alanine aminotransferase (IU/L)  16.7(7438) 20.8(87) 1.2(1.1-1.4)** 1.2(1.1-1.4)**
Corrected calcium (mmol/L) 2.33(7431) 2.30(87) -0.03(0.01)* -0.02(0.01)*
Cholesterol (mmol/L) 6.4(7430) 5.8(86) -0.6(0.1)** -0.5(0.1)**
Hdl (mmol/L) 1.2(6838) 1.1(82) -0.02(0.04) -0.05(0.04)
Ldl (mmol/L) 4.4(6654) 4.1(81) -0.3(0.1)* -0.3(0.1)*
Triglyceride (mmol/L) f 1.6(6850) 1.3(81) 0.8(0.7-0.9)** 0.8(0.7-0.9)**
Weight (kg) 71.6(7428) 68.6(87) -2.9(1.4)** -2.2(1.2)
Height (cm) 166.4(7427) 166.0(87) -0.5(1.0) -0.1(0.7)
Body mass index (kg/m2) 25.8(7425) 25.0(87) -0.8(0.4) -0.7(0.4)
Systolic blood pressure (mm/Hg) 137.0(7417) 134.1(87) -3.0(2.2) -1.6(2.0)
Diastolic blood pressure (mm/Hg) 82.5(7417) 80.1(87) -2.4(1.1)* -1.9(1.2)
Total spine BMD (g/cm2) 0.97(5035) 0.94(58) -0.03(0.02) -0.03(0.02)
Total hip BMD (g/cm2) 0.90(5024) 0.88(58) -0.02(0.02) -0.02(0.02)
§ adjusted for age group, gender, social class group and smoking status, * p<0.05, ** p<0.01, f geometric mean, ratio of geometric means and 95% CIs
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Table 2-5. Relation between participants with positive antiendomysial antibody
(EMA) test result and reported morbidity
Reported morbidity Odds ratio (95% CI)
EMA result No Yes Univariate p value*
n (%) n (%)
High blood pressure§
Negative 5876(81.4) 1347(18.6) 1
Positive 73(83.9) 14(16.1) 0.84(0.47-1.49) 0.6
High blood cholesterol
Negative 6188(87.6) 875(12.4) 1
Positive 81(93.1) 6(6.9) 0.52(0.23-1.20) 0.2
Stroke
Negative 7149(98.5) 109(1.5) 1
Positive 85(97.7) 2(2.3) 1.54(0.37-6.35) 0.4
Heart attack and/or angina
Negative 6778(93.3) 487(6.7) 1
Positive 85(97.7) 2(2.3) 0.33(0.08-1.34) 0.2
CVS combined
Negative 5570(76.6) 1701(23.4) 1
Positive 70(80.5) 17(19.5) 0.79(0.47-1.35) 0.5
Thyroid disease
Negative 6806(93.8) 446(6.2) 1
Positive 80(92.0) 7(8.0) 1.33(0.61-2.91) 0.6
Diabetes
Negative 7049(97.2) 202(2.8) 1
Positive 86(98.9) 1(1.1) 0.41(0.06-2.93) 0.7
Fracture of the wrist
Negative 6806(93.8) 452(6.2) 1
Positive 80(92.0) 7(8.0) 1.32(0.60-2.87) 0.6
Bronchitis/emphysema
Negative 6125(84.7) 1110(15.3) 1
Positive 79(90.8) 8(9.2) 0.56(0.27-1.16) 0.2
Asthma
Negative 6520(90.1) 720(9.9) 1
Positive 78(89.7) 9(10.3) 1.04(0.52-2.09) 1
Cancer
Negative 6853(94.5) 396(5.5) 1
Positive 82(94.3) 5(5.7) 1.05(0.43-2.62) 0.8
* F2 test with continuity correction or Fisher’s exact test, § except during pregnancy
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In 75 of 85 (88%) EMA positive participants and 5527 of 7015 (79%) EMA
negative participants, general health was reported as being “good or
excellent” giving an odds ratio of 1.76 (95% CI 0.90 to 3.46) adjusted for age,
gender, social class and smoking status. There was no difference in the
number of deaths recorded (EMA negative 591, 7.9%; EMA positive 5, 5.7%;
F2 p=0.579). Underlying cause of death given for the five EMA positive
participants were carcinoma of the pancreas, acute myeloid leukaemia,
ischaemic heart disease, carcinoma of the cervix and B cell lymphoma (not
otherwise specified).
Fourteen of 87 (16.1%) EMA positive participants and 315 of 7425 (4.2%)
EMA negative participants were found to be anaemic, giving an odds ratio of
4.56 (95% CI 2.53 to 8.21) adjusted for age, smoking status, gender and
social class. Of the EMA positive anaemic participants, 9 were women
(haemoglobin range 10.1 to 11.3 g/dl) and 5 were men (haemoglobin range
11.6 to 12.8 g/dl). In 7 of 58 (12.1%) EMA positive participants and 311 of
5024 (6.2%) EMA negative participants BMD at the hip showed
osteoporosis, giving an odds ratio of 3.08 (95% CI 1.31 to 7.25) adjusted for
age, BMI, smoking status and social class.
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2.5 Discussion
2.5.1 Principal findings
The study shows that undetected coeliac disease as assessed by EMA
positivity affects approximately 1% of this general population sample aged
45-76 years. In comparison with earlier screening studies the number of
EMA positive participants was sufficiently large to use data collected at
recruitment for comparisons with the EMA negative participants. Although
the positive participants were more likely to assess their own health as good
or excellent than the negative participants, some were mildly anaemic (16%)
or had evidence of osteoporosis (12%). In contrast they had a more
favourable cardiovascular risk profile in terms of having lower cholesterol
levels, slightly lower blood pressure and smoking less than the EMA negative
participants.
2.5.2 Limitations and merits
Unlike earlier studies it was not possible to confirm the diagnosis of coeliac
disease by intestinal biopsy in the EMA positive participants. The validity of
the findings therefore is mainly dependent on the specificity and, to a lesser
extent, the sensitivity of the EMA test. In routine clinical practice the test has
proved to be extremely accurate with a sensitivity of 94% and a specificity of
99% quoted recently.[67] Recent data from the laboratory in Derby
(unpublished) has estimated a specificity of 99.8% based on 1468 EMA
tests. In earlier screening studies a total of 57 participants have been found
to be EMA positive and in all but three a diagnosis of coeliac disease has
been supported by abnormal biopsy findings.[76, 79-84] The recent
introduction of the human tTGA assay in the laboratory allowed us to confirm
that 89% (77/87) of the EMA positives also had an abnormal tTGA level.[94]
The tTGA assay we used has also been shown to have high concordance
with EMA Therefore while it is possible that a few of the EMA positive
participants do not have abnormal intestinal histology, the results from the
tTGA assay indicate this is likely to be at most 11%. In addition the sensitivity
of the EMA test means that about 5% of those with coeliac disease will not
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have been detected which is therefore likely to be less than 5 missed cases
in this study.
I chose not to restrict the analyses to those positive for both tests for two
reasons. Firstly the sensitivity of human tTGA is not yet well-established; a
figure of 96% has been estimated recently.[68] Secondly the tTGA testing
was performed only on the EMA positive subjects whereas the EMA testing
was performed on the whole sample. When I compared those with both
EMA positive and abnormal tTGA results to the EMA negative participants
the associations presented here were of similar magnitude and in the same
direction. None of the associations were changed towards the null.
Although this was a general population sample there were greater numbers
of women and those from higher social class groups, which is likely to be a
consequence of the response rate to the original mailed invitation. I had no
information about the non-responders, but it seems unlikely that those
people who agreed to participate were, in some way, more likely to have
undetected coeliac disease and therefore biased the findings towards an
overestimate of seroprevalence.
2.5.3 Comparison with other studies
The seroprevalence estimate is similar to the findings of others who have
performed smaller screening studies in the UK.[77, 133] I found a trend
towards lower seroprevalence with lower social class, which is unexplained
and in contrast to many diseases. It would appear not to be completely
explained by smoking as the adjusted odds ratios show the same trend. The
numbers involved are small but the trend could possibly reflect events in
early life such as infant feeding practices that vary by social class and have
been shown to influence the development of coeliac disease in
childhood.[36, 134]
As might be expected with undetected coeliac disease the mean
haemoglobin, corrected calcium and total protein levels were lower in the
EMA positive participants and 16% had a mild anaemia compared with 4% of
the EMA negative participants. Overall most differences were small. The
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increases in serum alanine aminotransferase and in platelet counts were
small but similar to those found in clinically diagnosed coeliac disease.[50,
57] While there have been reports of significant decreases in bone mineral
density in screen-detected or subclinical coeliac disease, I have found only a
small, non-significant decrease in bone mineral density.[103, 105] However,
the prevalence of osteoporosis defined according to World Health
Organisation criteria was 12% in the EMA positives, twice that of the EMA
negatives.
The EMA positive participants did not regard themselves as unwell; indeed
the numbers reporting good or excellent health were greater than in the EMA
negatives, although this difference was not statistically significant. Reported
morbidity was no greater in the positives and there was a trend towards less
cardiovascular morbidity. The finding of an 8% reduction in serum
cholesterol among EMA positive participants would be expected to have a
significant impact on cardiovascular morbidity. It has been estimated that a
0.6 mmol/L lower cholesterol will confer a 25% reduction in incidence of
ischaemic heart disease.[135] The data suggest that undetected coeliac
disease may afford protection from ischaemic heart disease, a hypothesis
first raised by Whorwell et al some 25 years ago.[116]
I found that few of the EMA positives were smokers and that as a group they
reported much less smoking in the past. Four published case control studies
have examined the relationship between cigarette smoking and coeliac
disease. While three have found a positive association between not smoking
or never smoking and having coeliac disease, the one carried by Patel et al
did not.[39-42] In these studies it has not been clear how much of the
association might be accounted for by selection and reporting biases and by
cases stopping smoking after diagnosis. In addition while the proportion of
cases (people with coeliac disease) reporting current smoking (~40%) has
remained fairly consistent the amount of smoking in the control groups varied
considerably. The problem of selection bias for this relationship should not
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apply to my study and the findings therefore suggest that this is indeed a
causal relationship probably analogous to that seen in ulcerative colitis.
2.5.4 Summary
I have found that undetected coeliac disease is likely to affect about 1% of
the general population in England. Although these people are at increased
risk of mild anaemia and osteoporosis, they do not regard themselves as
unwell. The important finding of a favourable cardiovascular risk profile in
these individuals suggests that any screening programme of the general
population would need to be carefully evaluated in terms of risks and
benefits before its introduction.
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3 Description of the General Practice Research Database (GPRD) and
the coeliac disease dataset
3.1 Introduction
This section will describe the General Practice Research Database and how
the study population, disease status and other variables were defined that
are common to subsequent chapters. It contains the descriptive results of
the study population and the distribution of the other variables defined.
3.2 The General Practice Research Database
The General Practice Research Database (GPRD) is a longitudinal primary
care database and contains the computerised medical records from general
practice of more than 8 million of these registered people.[136-141] When
people are seen in primary care in the UK the majority of significant medical
diagnoses, information from hospital letters and discharge summaries, and
prescriptions are entered onto a desktop computer. These data are then
aggregated and anonymised to maintain patient confidentiality. The
database was started in 1987 under the name Value Added Medical
Products (VAMP), which was a geographically representative group of
doctors that collected data according to a research protocol that included
collection of all prescriptions and medically significant events.[142] At the
end of 1994, Reuters acquired VAMP database and gave it to the
Department of Health, who renamed the database the GPRD. Currently the
Medicine Control Agency manages the database. Practices are required to
record at least 95% of prescribing and relevant patient-encounter events and
there are regular routine validity checks.[141] The data practices contribute
on this basis is named “up-to-standard” data. Events that occur prior to the
“up-to-standard” period are also recorded if they are considered important
medical diagnoses.
Structurally the GPRD is a relational database divided into four data tables
linked by a unique identification string variable. The four tables contain
patient records, medical records, therapy records and prevention records.
The patient records contain information on date of birth, family identification
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code, gender, marital status, registration date, code for usual doctor, and
prescription exemption status. The medical records contain all the records
on medical diagnoses coded using Oxford Medical Information System
(OXMIS) and Read codes, each of which is coded with the event date.
OXMIS and Read codes are hierarchical codes commonly used in general
practices in England. Most of the data within the GPRD are coded with
OXMIS codes, but more recently many practices have converted to Read
codes. Data from the GPRD uses a combination of these codes depending
on the practice. Information from speciality consultations is also recorded in
this section. The third section is the therapy records and this contains all the
information on prescribing including the date of the prescription, the drug
details are coded using the prescription pricing authority system, quantity,
and the dosage instructions. The last section of the GPRD is the prevention
records, which contains information on other aspects of medical care such
as smoking status, contraception use and vaccines given.
3.2.1 Ethical approval
Ethical approval was given by the GPRD Scientific and Ethical Advisory
Group (Protocol number 361).
3.3 Limitations and merits of the GPRD
The GPRD has good qualities for use as a tool for disease based
epidemiology, but as with any data source it has limitations. The following
sections will address some of these merits and limitations. When designing,
carrying out and reporting the studies presented in the following chapters,
these factors were taken into consideration.
3.3.1 Size
For studies of coeliac disease one of the greatest strengths of GPRD is its
size. Although as many as 1% of the general population may have
undetected coeliac disease, as shown in section 1, the prevalence of
diagnosed coeliac disease is estimated to be approximately 0.1 to 0.3%. To
study the impact of such a relatively rare condition on specific (also relatively
rare) outcomes, such as fracture or malignancy requires a cohort of
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considerable size. The GPRD provides an opportunity to assemble such a
cohort and therefore has the potential to achieve precise estimates of risk.
3.3.2 Representative.
Although the practices in GPRD are self-selected they are from a wide
variety of different areas of the UK, and have been shown to have levels of
morbidity that are very similar to national estimates[137]. It is therefore
reasonable to generalise results from the GPRD to the population of the UK
as a whole.
3.3.3 Prospectively collected
The identification of each subject’s entry date to the dataset ensures that it is
easy to ascertain which data are prospectively, and which retrospectively
recorded. This is of particular importance for studies where measurement of
outcome may be biased, for example fracture. The data reflect the
occurrence of disease and subsequent management in primary care, so
when an outcome (fracture) occurs, or is notified to the general practitioner, it
is recorded. Although there is the potential for some misclassification of the
date of recording of medical diagnoses, this is unlikely to be the case for the
writing of a prescription, which are generated on the general practitioner’s
desktop computer contemporaneously.
3.3.4 Contemporary
For the studies involving survival analysis for outcomes in this thesis, for
example time to fracture and time to death I have used data from June 1987
to April 2002. These data represent the contemporary experience of people
with coeliac disease and their matched control cohort. For the outcomes I
have studied this represents an improvement on previous studies that, for
the most part, have used data further away in time from the present.
3.3.5 Validity
Although as outlined above strict data standards are maintained for the
GPRD, systems also exist for the independent validation of the data by third
parties. The mechanism for this is via the requesting of anonymised copies
of paper records, or the completion of questionnaires by general
practitioners. This system although it is sufficiently expensive (£70-200
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approximately per validated subject) to restrict its use does permit validation
of small samples. Using this system the GPRD has been extensively
validated for a wide range of diagnoses and consistently found to be
accurate[138, 143-146]. Described in section 3.5 is a small validation study
of the diagnosis of coeliac disease using this methodology that I have carried
out.
3.3.6 Duration of follow up
Although the GPRD is the largest available prospectively collected general
practice dataset, it is not as large as it first appears. There are no
prospective records prior to 1987. In addition both practices and people
have stopped contributing over the duration of the database. Therefore in
total there are a large number of people contributing to the database but for
relatively short periods. In practice this leaves relatively little person time
following diagnosis in incident cohorts.
3.3.7 Incomplete recording
One problem with the use of any routinely collected data such as the GPRD
is that what is recorded is determined not by the needs of the research, but
by what is felt relevant to the primary purpose of the data recording. This
means that recording is determined by the general practitioner’s assessment
of what is relevant to the ongoing primary medical care of subjects. Hence
not only is data incomplete, but it is likely that there is bias as to which data
are missing. For example it is likely that a general practitioner will record that
a patient drinks heavily if they know this as it may adversely affect health, it
perhaps less likely that they would record the knowledge that the patient was
teetotal unless they suffered from a condition which might be attributable to
alcohol.
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3.4 The coeliac disease dataset: study population and definitions
3.4.1 Coeliac disease and control status
Records were extracted of all persons within the GPRD between June 1987
and April 2002 with a recorded diagnosis of coeliac disease using the codes
listed in Table 3-1.
Table 3-1. Diagnostic codes for coeliac disease
Description Code Type of code
COELIAC DISEASE 2690B OXMIS
COELIAC DISEASE J690.00 READ
COELIAC DISEASE NOS J690z00 READ
GLUTEN ENTEROPATHY J690.13 READ
INFANTILE COELIAC DISEASE 2690D OXMIS
ACQUIRED COELIAC DISEASE J690100 READ
Where possible 5 control subjects were selected matched to each individual
with coeliac disease by age, gender, general practice and follow up time.
When selecting control subjects I excluded individuals who had any record of
coeliac disease, dermatitis herpetiformis, a gluten-free prescription or a non-
specific reference to coeliac disease e.g. “gluten free diet”, “gluten sensitivity”
using the codes listed in Table 3-2. Prescriptions were identified for gluten
free products from the GPRD drug index. Each control had to be alive and
contributing data on the date (index date) of the first occurrence in their
matched case’s record of any of the coeliac disease or gluten free product
codes, within up-to-standard data.
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Table 3-2. Medical codes used to exclude control selection
Code Description
2690B COELIAC DISEASE
J690.00 COELIAC DISEASE
J690z00 COELIAC DISEASE NOS
J690.11 COELIAC RICKETS
J690000 CONGENITAL COELIAC DISEASE
ZC2C200 DIETARY ADVICE FOR COELIAC DISEASE
J690.13 GLUTEN ENTEROPATHY
13B2.00 GLUTEN FREE DIET
8B55.00 GLUTEN-FREE DIET
2690D INFANTILE COELIAC DISEASE
8CA4200 PT ADVISED RE GLUTEN FREE DIET
2690E SENSITIVITY GLUTEN
J690100 ACQUIRED COELIAC DISEASE
J690.14 SPRUE - NONTROPICAL
693 DERMATITIS HERPETIFORMIS
M140.00 DERMATITIS HERPETIFORMIS
M142.00 JUVENILE DERMATITIS HERPETIFORMIS
M145200 SENILE DERMATITIS HERPETIFORMIS
3.4.2 Using a more restricted case definition
It is probable that not all of the individuals selected as having coeliac disease
in the way described in section 3.4.1 have the disease. To take account of
this possibility two additional more restricted case definitions were used. The
first method was to include only those people who in addition to having a
diagnostic code for coeliac disease had received at least one gluten free
prescription. The second method was to select as cases only those
individuals who had the use of any of the coeliac disease codes (Table 3-1)
at least twice throughout their whole general practice record (within and not
in up to standard data).
3.4.3 Date of diagnosis
Each person with coeliac disease was assigned a date of diagnosis defined
as the date of the first record of a coeliac disease code as defined in Table
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3-1 or a dermatitis herpetiformis code (see Table 3-2). Since general
practitioners enter some data for important historical events retrospectively
this date preceded the start of their GPRD up-to-standard record in some
cases. Each control was assigned a pseudo-diagnosis date identical to the
diagnosis date of their case.
3.4.4 Incident and prevalent status
I defined “incident” subjects with coeliac disease as those individuals whose
diagnosis date of coeliac disease or first prescription for a gluten free product
occurred at least 1 year after the beginning of their up-to-standard GPRD
record as this has been shown to reflect incident diagnoses in inflammatory
bowel disease, probably as around the time of registration with the practice
there is increased recording of chronic conditions[144]. All other subjects
with coeliac disease were defined as “prevalent”.
3.4.5 Age
Age was calculated for each subject in subsequent studies at the beginning
of follow up in each study. For the studies on fracture risk and vascular
disease, age at the start of up to standard data was used. For the study on
malignancy and mortality age at index date was used. Age was then
grouped into 8 categories.
3.4.6 Gender
All subjects have their gender recorded.
3.4.7 Smoking status
Smoking status is not recorded for all subjects in the GPRD. It is recorded
by the general practitioner if and when they enquire about it, and is therefore
based on the individual’s response to the doctor’s enquiry. Subjects’
smoking status was classified based upon the coding during up to standard
data in the medical and prevention tables of GPRD as unknown, non-
smoker, ex-smoker or current smoker. Smoking status was referred to by
Oxmis or Read codes. Categorisation of these codes and the codes used
are listed in Error! Reference source not found.. Subjects who appeared
in more than one of these categories at differing times were coded in the
category suggesting greatest smoking experience.
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3.4.8 Body mass index (BMI)
All data coding height (metres) and weight (kilograms) during up to standard
data recording were identified from the prevention table. Since BMI
measured across time in this way is not necessarily applicable in children it
was not calculated for subjects 15 years of age or younger. Inspection of the
data showed many impossible or highly unlikely values. Records of height
over 2.5 metres or under 1 metre were therefore ignored as being probable
errors as well as records coding a weight under 30kg. BMI (kgm-2) was then
calculated using the median values of the recorded heights and weights.
3.4.9 Gluten-free prescription rate
The number of gluten-free prescriptions was extracted from the therapy file
and divided by the observation time to calculate the rate of gluten-free
product prescription. This value was grouped into categories: none, up to
9.99 and 10 or more.
3.4.10 Visit rate
Visit rate was calculated as the number of unique calendar dates with a
medical diagnosis code divided by the observation time for each subject to
estimate the amount each person visited their general practitioner. This rate
was categorised by tertiles.
3.5 Validation of coeliac disease diagnosis
To evaluate the validity of the coeliac disease diagnosis in the studies using
the GPRD a stratified ( by prevalent/incident status and age group) random
sample (n=34) of people with coeliac disease (as identified in section 3.4.1)
were selected. In order to maximise responses the people with coeliac
disease selected were, according to the data available, not dead and
continuing to contribute to the GPRD. Using Comasco Computer Services
Ltd (the company licensed for processing requests to general practitioners
for more information) the general practitioners for each individual were
contacted by letter. Each general practitioner was asked to provide, where
possible, any confirmatory information available in the paper record relating
to the diagnosis of coeliac disease. They were provided with individual
identifiers and approximate age at and year of diagnosis. The returned
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documentation was then read and each person was assigned a definition of
his or her coeliac disease status as follows:
x Definitely not: no evidence of coeliac disease or a clear statement
saying that the individual did not have the disease
x Definitely yes: clear evidence of coeliac disease, for example an
appropriate histology report of a duodenal biopsy, or a clear statement
indicating that the individual has coeliac disease
x Probably yes: no clear evidence against the assumption of a
diagnosis of coeliac disease
3.6 Statistical analysis
Proportions were compared using F2 tests. The binomial distribution was
used to calculate confidence intervals (CI).
3.7 Results describing the study population
The results for this section are shown in Table 3-3.
3.7.1 Numbers in the cohorts and person years at risk
The cohorts included 4732 subjects with coeliac disease and 23620 matched
controls contributing 27116 and 149896 observed years at risk respectively.
3.7.2 Numbers with two diagnostic codes for coeliac disease
Of the 4732 people with coeliac disease there were 2761 (58.4%) with at
least two diagnostic codes in their whole general practitioner record.
3.7.3 Age
The mean age at diagnosis of the “incident” subjects with coeliac disease
was 44.7 years (SD 20.6). The cohorts were closely matched on age at the
start of up to standard data.
3.7.4 Gender
Of the people with coeliac disease 67% were female. The control cohort
was closely matched on gender.
3.7.5 Smoking status
Overall recorded smoking status varied between the people with coeliac
disease and controls (F2 95.5, p<0.001). There were more current smokers
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in the control cohort compared to the coeliac disease cohort (15.4% vs
13.0%).
3.7.6 Body mass index
Overall BMI varied between the people with coeliac disease and controls (F2
648.9, p<0.001). More individuals were underweight (BMI d 18.5) in the
coeliac disease cohort (4.2% vs 1.2%). Only 3.1% of people with coeliac
disease were obese compared to 8.1% in the control cohort.
3.7.7 Gluten-free prescriptions
Only 10% of the coeliac disease cohort had never received a gluten-free
prescription and over 54% had more than 10 prescriptions per year for gluten
free products.
3.7.8 Visit rate
The cut points for the creation of tertiles were at a visit rate of 8.2 and 15.5
visits per year of follow up. Greater than 50% of the coeliac disease cohort
were above the highest tertile of visit rate compared to only 29% of the
control cohort (F2 1303.1, p<0.001).
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Table 3-3. Description of the study population
Coeliac disease
cohort
Control cohort
(n=4732) % (n=23620) %
Median observed time (years) 5.7 6.4
Total observed time (years) 27116 149896
Female 3095 65.4 18545 65.4
Age groups at start of UTS record (years)
0-3 257 5.4 1521 6.4
>3-15 362 7.7 1664 7.0
>15-25 523 11.1 2813 11.9
>25-35 779 16.5 3782 16.0
>35-45 809 17.1 4066 17.2
>45-55 833 17.6 4113 17.4
>55-65 550 11.6 2707 11.5
>65-75 415 8.8 1994 8.4
>75 204 4.3 960 4.1
Smoking status
Non smoker 2082 44.0 8623 36.5
Ex-smoker 221 4.7 1265 5.4
Current smoker 613 13.0 3630 15.4
Unknown 1816 38.4 10102 42.8
Body mass index, kgm-2
Less than or equal to 18.5 197 4.2 273 1.2
18.51 to 25 2010 42.5 6949 29.4
25.01 to 30 653 13.8 4319 18.3
Greater than 30 148 3.1 1920 8.1
Unknown 1724 36.4 10159 43.0
Tertiles of visit rate
1st tertile 716 15.1 8874 37.6
2nd tertile 1503 31.8 7953 33.7
3rd tertile 2513 53.1 6793 28.8
Gluten free prescriptions per year of follow up
None 452 9.6
Between 0 and 10 1719 36.3
10 or more 2561 54.1
Individuals with at least two diagnostic
codes for coeliac disease
2761 58.4
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3.7.9 Validation of the coeliac disease diagnosis
Of the 34 individuals selected for validation there were 32 (94%) responses
from general practitioners. Of the 32 for which there was additional
information 26 (81.3% 95% CI 63.6%-92.7%) had definite or probable
coeliac disease (Table 3-4). Of those 26 only 3 had not had a prospectively
recorded gluten free prescription. Therefore using the definition of having
one diagnostic code and at least one prescription 23 (88.5% 95% CI 70.0%-
97.6%) had definite or probable coeliac disease. That proportion increased
when the definition requiring two diagnostic codes was used to 100% (one
sided 97.5% CI 78.2%). None of the 6 people who definitely did not have
coeliac disease had more than 1 coeliac code used, although three of them
had had a gluten free prescription.
Table 3-4. Validation of the three definitions of a coeliac disease diagnosis in
32 people with additional information available
One diagnostic code One diagnostic code
and at least one
gluten free
prescription
Two diagnostic codes
Coeliac disease
confirmed
Number Percent Number Percent Number Percent
Definitely not 6 18.8 3 11.5 0 0
Definitely yes 21 65.6 19 73.1 13 86.7
Probably yes 5 15.6 4 15.4 2 13.3
Total 32 100 26 100 15 100
3.8 Overall study design for subsequent studies
Having defined the study populations in sections 3.4 and 3.7 the subsequent
studies use this base population. In the studies on fracture risk, malignancy
and mortality the whole population is used. In the study on vascular disease
only those subjects over the age of 25 years are included. In general a
cohort analysis has been performed as each individual potentially enters and
exits prospective follow up (up to standard data) at different times. For the
cohort studies as some subjects are censored, either at the end of the follow
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up period (April 2002) or at the time they leave a contributing practice (at the
end of up to standard data), survival analysis was used to estimate the rate
of occurrence of events taking account of these unequal lengths of follow up.
In addition survival analysis, in particular the Cox proportional hazard’s
model, allows the baseline hazard to vary over time (which it conceivably
may do with the outcomes chosen) and therefore is appropriate (as long as
the assumptions of such modelling are met). The specific analysis strategies
are described in more detail for each separate study. Data manipulation and
analyses were carried out using the software Access 2000 and Stata 7 (Stata
corportation, Texas, USA).
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4 Fracture risk in people with coeliac disease
4.1 Introduction
This section will describe a study of the fracture risk in people with coeliac
disease compared to the general population.
4.2 Methods
4.2.1 Study population
I used the whole study population for this study as defined in section 3.4.
4.2.2 Outcomes and confounders
The main outcome measure was any fracture, and the observation time at
risk was between the beginning of the up to standard record and the end of
data collection for the overall and subgroup analyses. I also examined first
hip and radius/ulna fracture by the same method, and then multiple fractures
by extracting all diagnosis codes for any fracture. I extracted data for drug
exposures (e.g. oral and injected corticosteroids) for the time period before
outcome or the end of data collection and calculated a prescription rate for
each drug (number of prescriptions/observation time). I categorised
individuals into those who had none of the specific prescription, a few and
many. The latter two categories were split at the median of the prescription
rate for those who had one or more prescriptions. Potential drug
confounders included steroids, antidepressants, bisphosphonates and
hormone replacement therapy. A number of other potential confounders
including recorded falls and other co-morbid diagnoses (e.g. chronic
obstructive pulmonary disease) were extracted for the time period before
outcome or the end of data collection.
4.3 Statistical analysis
Initially I calculated crude age and gender specific fracture rates for the two
cohorts and then used Cox regression modelling to estimate the hazard ratio
(HR) of fracture in the coeliac disease cohort compared to the matched
control cohort, checking the proportional hazards assumption using the
diagnostic section within Stata. Kaplan-Meier graphs were plotted for each
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of the main outcome measures. For the multiple fractures analysis I used a
conditional risk set model[147]. The impact of potential confounders was
assessed using a series of multivariable models, retaining variables that led
to a change in the hazard ratio for coeliac disease of 10% or more. For
confounder variables, missing data were fitted as a separate category to
ensure that nested models contained the same number of individuals. To
assess possible interaction between coeliac disease and age group (age at
the beginning of up to standard data and at diagnosis), gender and
prevalent/incident status we performed stratified analyses and fitted
multiplicative interaction terms. Finally we explored any change in fracture
rates before and after diagnosis of coeliac disease in the “incident” subjects
only, by comparing the rates for these periods adjusted for age group.
4.4 Results
The results for the study population are shown in section 3.7. The
proportions of subjects with various potential confounding co- morbidities and
drug prescription rates are shown in Table 4-1. There was no excess of
recorded falls in the coeliac disease cohort and 2.2% had a diagnosis of
chronic obstructive pulmonary disease compared to 2.0% of the control
cohort.
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Table 4-1. Details of selected potential confounders
Coeliac disease
cohort
Control cohort
(n=4732) % (n=23620) %
Recorded number of falls
None 4560 96.4 22815 96.6
One 137 2.9 676 2.9
More than one 35 0.7 129 0.6
Chronic obstructive pulmonary disease
No 4626 97.8 23146 98.0
Yes 106 2.2 474 2.0
Diabetes (Type 1 and type 2)
No 4595 97.1 23018 97.5
Yes 137 2.9 602 2.6
Recorded number of prescriptions for:
Oral or injected steroids
None 3956 83.6 20909 88.5
A few 316 6.7 1409 6.0
Many 460 9.7 1302 5.5
SSRIs
None 4297 90.8 21966 93.0
A few 206 4.4 824 3.5
Many 229 4.8 827 3.5
Tricyclic antidepressants
None 4012 84.8 20747 87.8
A few 338 7.1 1456 6.2
Many 382 8.1 1415 6.0
Bisphosphonates
None 4629 97.8 23461 99.3
A few 47 1.0 80 0.3
Many 56 1.2 79 0.3
Hormone replacement therapy
None 3924 82.9 20240 85.7
A few 337 7.1 1756 7.4
Many 471 10.0 1622 6.9
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4.4.1 Numbers and rates of fracture
There were 356 recorded first fractures in the coeliac disease cohort, and 24
recorded hip fractures. The overall rate of any fracture for the coeliac
disease cohort was 137.9 per 10000 person years compared to 105.9 per
10000 person years in the control cohort (Table 4-2). The crude rates of all
fracture by age group, gender and disease status are shown in Figure 4-1.
There was approximately a 30% increase in the risk of any fracture for the
coeliac disease cohort compared to the control cohort (HR 1.30 95% CI
1.16-1.46)). When restricted to an analysis of hip fracture or ulna/radius
fracture the hazard ratios were increased to 1.90 (95% CI 1.20-3.02) and
1.77 (95% CI 1.35-2.34) respectively.
In the multivariate analyses, none of the potential confounders I assessed
made any substantial impact on the coefficients for the coeliac disease
cohorts, so they were not included in the final models. The absolute
difference in the rate of any fracture overall was 3.20 fractures per 1000
person years. For hip fracture, in those over 45 years of age, the rate
difference was 0.97 per 1000 person years and in those over 75 years 2.35
per 1000 person years. Figure 4-2 shows the overall Kaplan-Meier plots for
any fracture, hip and ulna/radius fracture by disease status.
4.4.2 Incident/prevalent cases
When I analysed the subjects with an “incident” diagnosis of coeliac disease
I found slightly reduced hazard ratios in comparison with both the overall
hazard ratios for all subjects and compared to those in the “prevalent” group.
However I found no statistically significant evidence of interaction. The
fracture rate after diagnosis of coeliac disease in those with an incident
diagnosis was 145.2 per 10000 person years in comparison with 122.8 per
10000 person years before diagnosis (Table 4-3). When adjusted for age
the hazard ratio for the period after diagnosis compared to before was 1.07
(95% CI 0.77-1.50).
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4.4.3 Multiple fractures
Of the control cohort 183 (0.8%) had more than one fracture compared to 50
(1.0%) of the coeliac disease cohort. The hazard ratio estimated for risk of
multiple fractures within each individual showed no substantial difference
from the overall findings for any fracture (HR 1.28 (95% CI 1.15-1.42)). In
addition there was no interaction between age group and coeliac disease
status with respect to multiple fracture.
4.4.4 Restriction analyses
When I repeated the analyses restricted to only those subjects with coeliac
disease who had had at least one gluten-free prescription I found no
important differences in the risk estimates (Table 4-4). Nor were there any
differences when I restricted to including only cases with at least two coeliac
disease medical codes.
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Figure 4-1. Crude rates (95% CI) of any fracture by age group, gender and
disease status
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Table 4-2. Number, rate and crude hazard ratios for the coeliac disease cohort compared to the control cohort, overall and limited to prevalent
and incident subjects with coeliac disease
Prevalent subjects Incident subjects
Overall with coeliac disease$ with coeliac disease$
Number of Rate Hazard Rate Hazard Rate Hazard
N** fractures (10000yr-1) ratio 95% CI N** (10000yr-1) ratio 95% CI N** (10000yr-1) ratio 95%CI
Any fracture
Control cohort* 23616 1524 105.9 1 15671 103.8 1 7945 109.3 1
Coeliac disease cohort 4732 356 137.9 1.30 (1.16-1.46) 3143 144.2 1.40 (1.20-1.62) 1589 129.5 1.19 (0.99-1.42)
Hip fracture
Control cohort* 23620 71 4.7 1 15675 4.6 1 7945 4.9 1
Coeliac disease cohort 4732 24 8.9 1.90 (1.20-3.02) 3143 11.1 2.41 (1.37-4.23) 1589 6.0 1.23 (0.54-2.81)
Ulna/radius fracture
Control cohort* 23619 210 14.1 1 15674 12.2 1 7945 17.3 1
Coeliac disease cohort 4732 67 24.9 1.77 (1.35-2.34) 3143 25.5 2.13 (1.48-3.07) 1589 24.2 1.40 (0.92-2.14)
* baseline category
** total numbers vary as those individuals who had a fracture on the same date as the start of their GPRD record began were excluded
$ for these analyses only the matched controls of those subjects with coeliac disease included were used
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Figure 4-2. Kaplen-Meier survival plots for any fracture, hip fracture and ulna/radius fracture
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Table 4-3. Number, rate and hazard ratio of any fracture before and after diagnosis in 1589 subjects with an incident diagnosis of
coeliac disease
Number Person Rate 95% CI Hazard 95% CI
of fractures years (10000yr-1) ratio**
Before diagnosis* 87 7082 122.8 99.6 151.6 1
After diagnosis 61 4201 145.2 113.0 186.6 1.07 (0.77-1.50)
* baseline category
** adjusted for age at start of observation time
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Table 4-4. Any fracture, hip fracture and ulna/radius fracture analyses restricted to those cases with 1 coeliac code plus at least one
gluten free prescription and to those cases with 2 coeliac codes
Subjects with 1
coeliac code
Subjects with 2 coeliac
codes
plus at least one (n=2761)$
gluten free prescription
(n=4280)$
Hazard 95% CI Hazard 95% CI
ratio ratio
Any fracture
Control cohort* 1 1
Coeliac disease cohort 1.31 (1.16-1.48) 1.30 (1.12-1.50)
Hip fracture
Control cohort* 1 1
Coeliac disease cohort 1.99 (1.25-3.18) 1.97 (1.07-3.64)
Ulna/radius fracture
Control cohort* 1 1
Coeliac disease cohort 1.84 (1.39-2.44) 1.81 (1.35-2.34)
* baseline category
$ for these analyses only the matched controls
of those subjects with coeliac disease included were used
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4.4.5 Proportional hazard’s assumption
In the analysis of hip fracture the ph test for evidence against the
proportional hazard’s assumption gave p<0.9. The log –log plot for the same
analysis is shown in Figure 4-3. In the plot of Schoenfeld residuals there
was only small variation in the hazard over time seen (Figure 4-4). As with
the hip fracture analysis there was little evidence against the proportional
hazard’s assumption in any of the other presented models.
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Figure 4-3. Log -log plots of hip fracture analysis
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Figure 4-4. Plot of schoenfeld residuals against time for the hip fracture
analysis
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4.5 Discussion
4.5.1 Principal findings
The results of the study show modest increases in the relative risk of any
fracture (30% increase), hip fracture (90% increase) and ulna/radius fracture
(77% increase) among people with coeliac disease compared to the general
population. Nonetheless, the increases in absolute risk of fracture were
modest being 3.19 fractures per 1000 person years and 0.97 per 1000
person years in those over age 45 for hip fracture alone. These increases in
risk were slightly less in individuals with coeliac disease diagnosed more
recently. Additionally, in the subjects with “incident” coeliac disease, I found
no difference in the risk of fracture in the period after diagnosis compared to
before diagnosis (HR 1.07 (95% CI 0.77-1.50)).
4.5.2 Limitations and merits
In the study people with coeliac disease were more frequent attenders at
their general practitioner than members of the general population. It is
therefore possible that I have overestimated the relative rate of any fracture
in the coeliac disease cohort compared to the control cohort as a
consequence of less complete recording of medical events in a “healthy”
group. However this is unlikely to have been a problem with hip fracture,
where ascertainment is likely to be high. In contrast, the risks of fracture
may be an underestimate due to random error in the definition of both
coeliac disease status and fracture diagnoses. However, the accuracy of
medical diagnoses within the GPRD is known to be high, specifically with
respect to fracture[145] and the crude age and gender specific rates for any
fracture are similar to those reported by others in the United Kingdom[148].
Furthermore, there have been several validation studies of the GPRD,
including one that has looked in detail at the accuracy of the diagnosis of
inflammatory bowel disease (IBD)[137, 138, 144]. In this study Lewis et al
found that the IBD diagnosis within the GPRD was highly probable or
probable in 92% (95% CI 86 to 96%) of their surveyed cases. IBD is
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analogous to coeliac disease in that it is a diagnosis made in secondary care
and their findings are likely to be generalisable to the study.
In addition, I believe that there will be very few people with a recorded
diagnosis of coeliac disease and coexisting prescriptions for one or more
gluten free products who do not have coeliac disease. One reason for this is
that general practitioners in the UK have a limited prescribing budget, which
means that they are unlikely to write an unnecessary and expensive
prescription, such as for a gluten free product, unless they have good
reason. When I restricted the analyses to those people with coeliac disease
who also had at least one gluten free prescription, to increase the specificity
of the coeliac disease diagnosis, there was no substantial change in the
effect. When I was even more restrictive in the coeliac disease definition, by
including only people with at least two diagnostic codes for coeliac disease,
the estimates were again very similar to the overall findings.
The definition of an incident case is a pragmatic one based on the
assumption that an important medical diagnosis such as coeliac disease
should be coded accurately in the historical records or within a year of the
person registering with a GPRD practice and it is similar to the “incident”
definition of IBD that was validated by Lewis et al. It is possible that a person
with coeliac disease might not see their GP for 5 years or more and therefore
be incorrectly categorised as “incident”, however I think the numbers are
likely to be small. Should there be misclassification between prevalent and
incident cases, this may have led to an underestimate of the differences in
fracture risk between the prevalent and incident groups. The finding of a
lack a gluten free prescription in 10% of those people recorded as having
coeliac disease might suggest that they have been incorrectly labelled. I
think it is as likely that either they purchase their gluten free products over
the counter, or that they have mild disease and do not comply with a gluten
free diet.
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As the GPRD does not contain information on socio-economic status I have
been unable to control for this in the analysis and since people with coeliac
disease have tended to be in higher socio-economic groups (section 1), this
could have led to an underestimate of fracture risk. This would only be the
case if there is a strong link between socio-economic status and fracture risk
for which there is not strong evidence. The control cohort was closely
matched in terms of age, gender and community to minimise the potential for
confounding by these factors and I had the ability to assess the impact of
potential confounders such as BMI, smoking status, co- morbidity and drug
exposures on fracture risk. In the event I found no evidence of substantial
confounding, although I acknowledge the presence of missing data for some
of these variables. It seems unlikely that I have therefore greatly under or
over estimated the fracture risk due to any residual confounding.
The study included 4732 people with coeliac disease who contributed more
than 27000 person years at risk and had over 350 fractures. It is the largest
study of fracture risk in coeliac disease published to date. As a
consequence of its size and the cohort design I have been able to estimate,
with reasonable precision, both the absolute and relative risks of any fracture
and also for specific fracture subgroups. I have also assessed multiple
fractures and explored the effect of treatment on fracture risk. I believe that
the results are therefore likely to be generalisable to people with diagnosed
coeliac disease elsewhere and can be considered to reflect contemporary
risk of fracture. When I took multiple fractures into account in the analysis
there was no substantial change in the risk estimate nor were older people
with coeliac disease more at risk of multiple fractures. This suggests that I
have not underestimated the relative incidence of fracture in people with
coeliac disease by restricting the analyses to their first recorded fracture
occurrence. Many studies have shown that the clinical presentation of
diagnosed coeliac disease has changed in recent times compared to that
seen in the 1960’s and 70’s[50-53, 98]. The finding of slightly greater
relative risks in the prevalent group may reflect that change i.e. that those
people diagnosed with coeliac disease in recent times have not had such
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severe malabsorption and consequent malnutrition prior to diagnosis, and
therefore have less risk of osteoporosis and fracture. Alternatively it may be
that prevalent cases with a longer duration of treated disease have an
increased fracture risk, although there is no evidence that the rate of
decrease of bone mineral density in coeliac disease whilst on a gluten free
diet is greater than the general population.
4.5.3 Comparison with other studies
The results can be compared with the findings of previous studies of fracture
risk in coeliac disease. Vasquez et al compared the fracture experience of
165 patients (median age 40 years) with that of controls with functional
gastrointestinal disorders and found a three-fold increase in overall fracture
risk (Odds ratio OR 3.5 95% CI 1.8-7.2) based on 25% of patients reporting
fractures and only 8% of controls[112]. A subsequent study from the same
group found that the increase in fracture experience was confined to people
with coeliac disease presenting with “classical malabsorption” (OR 5.2 95%
CI 2.8-9.8)[115]. Fickling et al reported a “relative risk” of fracture of 7 based
on a survey of 75 patients with a mean age of 52 years and age and sex
matched controls selected from patients who had attended for bone
densitometry[114]. While 21% of their patients with coeliac disease reported
a past fracture, only two (3%) of the controls did. The differences between
the findings and these two studies are likely to be due to a combination of
the over-representation of more severe disease in their subjects with coeliac
disease, and low fracture rates in the control groups. The results are more in
keeping with two recent population based studies of fracture risk in coeliac
disease. Both Vestergaard et al, in a database study of 1021 hospital
diagnosed subjects with coeliac disease, and Thomason et al, using a
mailed questionnaire survey of 244 cases, found no increase in the overall
fracture risk compared to the general population but with wide confidence
limits[111, 113].
4.5.4 Summary
The findings confirm that overall people with diagnosed coeliac disease have
a small increased risk of fracture and that the excess risk was lower in those
diagnosed more recently. The risks of “osteoporotic” fracture such as hip
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and ulna/radius are higher than the overall risk but are, at most, moderate.
Although the results do not relate to people with previously undetected
coeliac disease it seems unlikely that the fracture risks in this group will be
substantially greater than I have found for clinically diagnosed disease, as I
have previously shown that the risk of osteoporosis in the former group is
small[149]. Some groups have suggested that all newly diagnosed adults
with coeliac disease should be screened for osteoporosis, either at diagnosis
or following one year of treatment with a gluten free diet[43, 109, 110]. More
data are needed on the safety, efficacy and cost-effectiveness of such
screening programs in coeliac disease before they are universally
recommended.
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5 Risk of vascular disease in adults with coeliac disease
5.1 Introduction
This section will describe a study of the risk of hypertension, high cholesterol,
atrial fibrillation, myocardial infarction and stroke in adults with coeliac
disease compared to the general population.
5.2 Methods
I used two approaches in this study: firstly I compared the risk of “persistent”
conditions (hypertension, high cholesterol and atrial fibrillation) in coeliac
disease compared to the general population using all available GPRD data
(cross-sectional design), and secondly I used a historical matched cohort
study design for acute myocardial infarction and stroke where the
observation time (person years at risk) for individuals included in the study
started at the beginning of their up to standard GPRD record.
5.2.1 Study population
I used the study population as defined in section 3.4. Selection for this study
was restricted to those people with coeliac disease aged 25 years or over at
the beginning of their up-to-standard data period, and their matched controls.
The age cut off was chosen arbitrarily to limit the study population to adults.
5.2.2 Outcomes and confounders
I investigated the risk of a diagnosis of hypertension, high cholesterol or atrial
fibrillation at any time in the available data and rate of first myocardial
infarction or stroke during up to standard GPRD data for the cohort analysis.
In addition I calculated a composite measure of hypertension that was
positive only if subjects had both a diagnosis of hypertension and had ever
had a prescription for an anti-hypertensive medication. Similarly I calculated
a composite measure of hypercholesterolaemia that was positive if subjects
had both a diagnosis of high cholesterol and had a prescription for a lipid-
lowering medication. Potential confounders including the recorded presence
or absence of diabetes and other co-morbid diagnoses (e.g. thyroid disease)
were extracted from all the available data (including data not in the up to
standard period).
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5.3 Statistical analysis
To compare the risk of each “persistent” condition in adults with coeliac
disease to the control population I calculated odds ratios for ever having a
diagnosis of hypertension, high cholesterol and atrial fibrillation using
conditional logistic regression. For the cohort analysis I calculated crude age
and gender specific myocardial infarction and stroke rates for the two cohorts
and then used Cox regression modelling to estimate the hazard ratio (HR) of
myocardial infarction or stroke in the coeliac disease cohort compared to the
matched control cohort. I plotted Kaplan-Meier graphs and checked the
proportional hazards assumption of the models. The impact of potential
confounders was assessed using a series of bivariable models, retaining
variables that led to a change in the hazard or odds ratios for coeliac disease
of 10% or more. For confounder variables, missing data were fitted as a
separate category to ensure that nested models contained the same number
of individuals. I checked for any evidence of interaction between disease
status and both body mass index and prevalent/incident status by fitting
multiplicative interaction terms.
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5.4 Results
The study included 3590 subjects with coeliac disease and 17925 matched
controls contributing 21248 and 117210 observed years at risk respectively.
The groups were closely matched on age at the start of the GPRD record
and gender (Table 5-1). There were more current smokers in the control
cohort (16.9% vs 13.7%). There was no excess of recorded diabetes in the
coeliac disease group (3.5% vs 3.7%) and 7.0% had a diagnosis of thyroid
disease compared to 3.2% of controls. Mean systolic blood pressure was 5
mmHg lower in the coeliac disease group.
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Table 5-1. Characteristics of the adults with coeliac disease and their matched
controls
Coeliac disease Controls
(n=3590) % (n=17925) %
Median observed time (years) 5.9 6.6
Total observed time (years) 21248 117210
Female 2461 68.6 12285 68.5
Age groups at start of GPRD record (years)
=<35 779 21.7 4085 22.8
>35-45 809 22.5 4066 22.7
>45-55 833 23.2 4113 23.0
>55-65 550 15.3 2707 15.1
>65-75 415 11.6 1994 11.1
>75 204 5.7 960 5.4
Smoking status
Non smoker 1818 50.6 7553 42.1
Ex-smoker 203 5.7 1156 6.5
Current smoker 490 13.7 3029 16.9
Unknown 1079 30.1 6187 34.5
Body mass index, kgm-2
Less than or equal to 18.5 155 4.3 202 1.1
18.51 to 25 1746 48.6 5923 33.0
25.01 to 30 608 16.9 4057 22.6
Greater than 30 140 3.9 1808 10.1
Unknown 941 26.2 5935 33.1
Diabetes ever recorded
No 3463 96.5 17258 96.3
Yes 127 3.5 667 3.7
Thyroid disease ever recorded
No 3340 93.0 17358 96.8
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Yes 250 7.0 567 3.2
Systolic blood pressure, mmHg (mean, sd) 129.5 19.4 134.6 20.0
Diastolic blood pressure, mmHg (mean, sd) 77.0 9.5 80.0 9.9
Blood pressure not recorded 821 22.9 4701 26.2
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5.4.1 Numbers, proportions and risks of hypertension, high cholesterol and
atrial fibrillation
Overall 408 (11%) of the adults with coeliac disease had ever had a
diagnosis of hypertension compared to 2765 (15%) in the control group
giving an unadjusted odds ratio (OR) of 0.68 (95% CI 0.60 to 0.76) as shown
in Table 5-2. This relationship was partly explained by body mass index, as
after adjusting for this variable the odds ratio was 0.78 (95% CI 0.69 to 0.87).
When I repeated the analyses using the composite measure of diagnosed
hypertension (including prescriptions), the results were similar. When I
repeated the analyses using the composite measure of
hypercholesterolaemia the results were again similar. The unadjusted odds
ratios for atrial fibrillation and high cholesterol diagnoses were 1.26 (95% CI
0.97 to 1.64) and 0.58 (95% CI 0.47 to 0.72) respectively. Adjusting for body
mass index had no appreciable effect on these latter two estimates.
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Table 5-2. Analysis of risk of hypertension, atrial fibrillation and high cholesterol diagnoses in 3590 people with coeliac disease
compared to 17925 controls using conditional logistic regression
Overall number Unadjusted Adjusted**
with disease (%) odds ratio 95% CI odds ratio 95% CI
Hypertension
Control* 2765 (15.4) 1 1
Coeliac disease 408 (11.4) 0.68 (0.60 to 0.76) 0.78 (0.69 to 0.87)
Atrial fibrillation
Control* 305 (1.7) 1 1
Coeliac disease 76 (2.1) 1.26 (0.97 to 1.64) 1.28 (0.98 to 1.67)
High cholesterol
Control* 866 (4.8) 1 1
Coeliac disease 107 (3.0) 0.58 (0.47 to 0.72) 0.60 (0.49 to 0.74)
* baseline category
** adjusted for body mass index
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5.4.2 Numbers and rates of myocardial infarction and stroke
There were 52 recorded first myocardial infarctions in the coeliac disease
cohort, and 62 recorded first strokes. The overall rate of myocardial
infarction for the coeliac disease cohort was 24.7 per 10000 person years
compared to 29.2 per 10000 person years in the control cohort (Table 5-3).
There was approximately a 15% decrease in the risk of myocardial infarction
for the coeliac disease cohort compared to the control cohort (HR 0.85 (95%
CI 0.63-1.13)). The overall rate of stroke was 29.4 per 10000 person years
in the coeliac disease group and the hazard ratio was 1.29 (95% CI 0.98-
1.70). In the multivariate analyses, only body mass index of the potential
confounders I assessed made any substantial impact on the coefficient for
myocardial infarction in coeliac disease altering the overall hazard ratio to
0.95 (95% CI 0.71 to 1.27). For stroke, only the presence or absence of
diagnosed hypertension altered the hazard ratio appreciably, to 1.40 (95% CI
1.06 to 1.84). In contrast, when adjusted for smoking status, the hazard
ratios were 0.87 (95% CI 0.65-1.16) and 1.33 (95% CI 1.00-1.75)
respectively. Figure 5-1 shows the Kaplan-Meier plots for myocardial
infarction and stroke (crude analysis).
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Figure 5-1. Kaplan-Meier survival plots for myocardial infarction and stroke
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5.4.3 Incident/prevalent cases
When I analysed only the subjects with an “incident” diagnosis of coeliac
disease I found a slightly reduced hazard ratio for myocardial infarction (HR
0.75 (95% CI 0.46-1.23)) and a slightly increased hazard ratio for stroke (HR
1.60 (95% CI 0.99-2.59)) in comparison with both the overall hazard ratios
for all subjects and compared to those in the “prevalent” group. However we
found no statistically significant evidence of interaction.
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Table 5-3. Number, rate and crude hazard ratios for the coeliac disease cohort compared to the control cohort, overall and limited to
prevalent and incident subjects with coeliac disease
Prevalent subjects Incident subjects
Overall with coeliac disease$ with coeliac disease$
Number Rate Hazard Rate Hazard Rate Hazard
N of events (10000yr-1) ratio 95% CI N (10000yr-1) ratio 95% CI N (10000yr-1) ratio 95%CI
Myocardial infarction
Control cohort* 17925 339 29.2 1 11775 31.3 1 6150 25.8 1
Coeliac disease cohort 3590 52 24.7 0.85 (0.63-1.13) 2360 28.8 0.92 (0.64-1.32) 1230 19.5 0.75 (0.46-1.23)
Stroke
Control cohort* 17925 265 22.7 1 11775 27.9 1 6150 14.8 1
Coeliac disease cohort 3590 62 29.4 1.29 (0.98-1.70) 2360 33.7 1.19 (0.85-1.68) 1230 23.8 1.60 (0.99-2.59)
* baseline category
$ for these analyses only the matched controls of those subjects with coeliac disease included were used
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5.4.4 Restriction analyses
When I repeated the analyses restricted to only those adults with coeliac
disease who had at least one gluten free prescription all the results were
similar. When I only included those cases with two or more diagnostic codes
for coeliac disease the majority of results were slightly different, although all
within the previous confidence intervals. In the latter case the odds ratios for
hypertension, high cholesterol and atrial fibrillation were 0.67, 0.58, 1.07.
For myocardial infarction and stroke the hazard ratios were 0.99 and 1.23
respectively.
5.4.5 Proportional hazard’s assumption
There was no clear evidence against the proportional hazard’s assumption in
this study. The log –log plots and schoenfeld residual plots for the
myocardial infarction analysis are shown in Figure 5-2 and Figure 5-3
respectively.
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Figure 5-2. Log -log plot for myocardial infarction analysis
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Figure 5-3. Plot of schoenfeld residuals against time for myocardial infarction
analysis
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5.5 Discussion
5.5.1 Principal findings
The results of the study show a marked decrease in the risk of diagnosed
hypertension and high cholesterol, yet a slight increase in the risk of atrial
fibrillation in adults with coeliac disease compared to the general population.
These factors appear to have slightly different effects on vascular disease,
as the point estimates suggest that there is approximately a 15% reduction
(95% CI 37% reduction to 16% increase) in the risk of myocardial infarction
but approximately a 30% increase (95% CI 2% reduction to 70% increase) in
the risk of stroke. The contrasts in these findings were slightly greater in
individuals with coeliac disease diagnosed more recently.
5.5.2 Limitations and merits
Adults with coeliac disease are more frequent attenders at their general
practitioner than members of the general population (section 3.7.8). As a
consequence, if ascertainment bias is present, it is possible that I have
underestimated the risk of stroke and atrial fibrillation in the control cohort
due to less complete recording of medical events in a “healthy” group.
Similarly I may have underestimated the decrease in relative risk of
hypertension, high cholesterol and myocardial infarction. It is also possible
that I have underestimated the effect sizes through misclassification of
unrecorded coeliac disease i.e. that some of the control group may have
coeliac disease. To check the validity of my diagnostic definitions I repeated
the analyses with the more restrictive definitions described earlier. When I
restricted the analyses to those adults with coeliac disease who also had at
least one gluten free prescription, to increase the specificity of the coeliac
disease diagnosis, there was no substantial change in the effect estimates.
When I included only cases who had at least two diagnostic codes for
coeliac disease, the majority of the findings were similar to those found
overall.
As the GPRD does not contain information on socio-economic status I have,
as before, been unable to control for this important variable in the analyses
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and since adults with coeliac disease have tended to be in higher socio-
economic groups, this could explain part of their marginally lower incidence
of cardiovascular disease (section 1). The control cohort was closely
matched in terms of age, gender and community to minimise the potential for
confounding by these factors and I had the ability to assess the impact of
potential confounders such as body mass index, smoking status and co-
morbidity on vascular disease risk. Although adjusting for body mass index
and the diagnosis of hypertension altered the effect estimates for myocardial
infarction and stroke respectively, both can be considered as intermediate
steps between coeliac disease and the outcome. Rather than being
alternative explanations for the observed association, they are more likely to
be on the causal pathway between coeliac disease and vascular disease. I
found no other evidence of substantial confounding.
5.5.3 Interpretation
Although not statistically significant at the 5% level, the point estimates for
the risks of stroke and myocardial infarction are intriguing. Based on my
findings in section 1 where people with undetected coeliac disease had lower
serum cholesterol and slightly lower blood pressure a lower risk for
myocardial infarction might be expected. However the reduction in risk was
not as great as might have been predicted by the earlier study (i.e. a 10%
reduction in cholesterol leading to a 25% reduction in the incidence of
myocardial infarction). It is possible, for example, that the observed
relationship with myocardial infarction may have been attenuated by the
effect of treatment with a gluten free diet. Although I have previously shown
that people with undetected coeliac disease have lower serum cholesterol
than the general population (section 1) it is possible that following treatment,
and the subsequent improvement in intestinal absorption, serum cholesterol
may increase therefore attenuating any protective effect. The relationship is
clearly complex in view of the finding that plasma homocysteine levels
remain high in people with treated coeliac disease even after many years of
gluten exclusion[150] which may counteract any beneficial effect of lower
cholesterol[151]. The analysis of incident and prevalent cases adds some
support to the idea that treatment with a gluten free diet may alter the
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vascular disease risk profile of these individuals. The finding of an increased
risk of stroke was not explained by the greater prevalence of thyroid
disorders or atrial fibrillation in the coeliac disease group, although it is
possible that the latter condition is under recorded in primary care as only
13% of the subjects who had had a stroke in the study had atrial fibrillation.
With less hypertension, lower body mass index and presumably lower
cholesterol, it was surprising to find, albeit modest, contrasting relationship to
that with myocardial infarction. One explanation may be the previously
documented finding of a high prevalence of coeliac disease in idiopathic
cardiomyopathy[152], suggesting that the mechanism of increased risk in
coeliac disease might be arrythmogenic or thromboembolic. Alternatively the
recently postulated neurotoxic effects of gluten may play an important
role[153].
5.5.4 Summary
The findings confirm the hypothesis that adults with diagnosed coeliac
disease have a decreased risk of hypertension and hypercholesterolaemia.
The finding of a slightly decreased risk of myocardial infarction and a small
increased risk of stroke in coeliac disease are intriguing and lead to
speculation about the mechanisms of vascular disease, particularly in
relation to nutritional status.
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6 Malignancy and mortality in people with coeliac disease
6.1 Introduction
This section describes a study of the risk of malignancy and mortality in
people with coeliac disease compared to the general population. This
section also includes an estimate of life expectancy in people with coeliac
disease compared to the general population.
6.2 Methods
6.2.1 Study population
I used the study population already described in sections 3.4 and 3.7.
6.2.2 Outcome data
For the outcomes, I extracted data that included the date of first occurrence
of any malignancy, first occurrence of specific malignancy subgroups and
date of death. I defined all malignancies by using the relevant codes in the
GPRD database mapped to International Classification of Diseases (ICD) 9
codes[132]: 140-208 and 230-234. The specific malignancy groups I chose
were: all gastrointestinal cancer (ICD 9 150-154), lung cancer (ICD 9 162-
163), breast cancer (ICD 9 174-175), prostate cancer (ICD 9 185) and
lymphoproliferative disease (ICD 9 200-202). To identify death I used a
combination of Oxmis and Read coding and the subject’s registration status
within GPRD to assess whether they had died. Where a subject was multiply
recorded as having died I used the earliest recorded date to define the date
of death. The origin of the time axis and the entry of the subject to the study
were both set as the index date (the matched case’s relevant date was used
for controls).
6.3 Statistical analysis
Initially I calculated crude cancer incidence and mortality rates for the coeliac
disease and control cohorts. I used Cox regression modelling to estimate
the hazard ratio (HR) comparing outcomes in the coeliac disease cohort
compared to the control cohort plotting appropriate Kaplan-Meier graphs. I
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checked the proportional hazards assumption of each model. The possible
confounding effects of body mass index and smoking status were assessed
using a series of multivariable models, retaining variables that led to a
change in the hazard ratio for coeliac disease of 10% or more. For
confounder variables, missing data were fitted as a separate category to
ensure that nested models contained the same number of individuals. To
assess possible interaction between coeliac disease status and age group or
gender I performed stratified analyses and fitted multiplicative interaction
terms as appropriate.
To assess the robustness of the initial analyses, I performed a series of
sensitivity analyses. To assess ascertainment bias, i.e. whether any
increase in cancer risk was related to increased investigation as a result of
having either a diagnosis of coeliac disease or cancer made, I examined the
hazard ratios for each outcome within the first year after diagnosis and
during subsequent follow up. To assess the validity of the findings with
respect to possible misclassification of coeliac disease status, I restricted the
analyses to only those subjects with coeliac disease who had had at least
one prescription for a gluten-free product. I also restricted to those with two
codes for coeliac disease. To assess the possibility of survival bias, as the
cohort contained prevalent cases of coeliac disease, I stratified the censored
analysis by prevalent/incident status.
6.3.1 Indirect standardisation analysis
As the majority of previous mortality studies of coeliac disease have used
population data as their comparison I additionally compared the mortality
experience of both the coeliac cohort and the cohort control to that of the
population of England and Wales. To do this I carried out an age, sex and
period indirect standardisation of each cohort to where the expected deaths
were estimated from the population of England and Wales. This analysis
was truncated at 1/01/2000 as that was the extent of the available data.
6.3.2 Life table analysis
To further aid interpretation of any mortality associated with coeliac disease I
additionally used a life table analysis. To determine the life expectancy of
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people with coeliac disease compared to the general population I
constructed life tables from the age-specific mortality rates.
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6.4 Results
The cohorts included 4732 people with coeliac disease and 23620 matched
controls contributing 18923 and 94323 person years at risk respectively (Table
6-1). There was less person time at risk in this study (compared to earlier
sections in this thesis (3.7.1 and 3.4)) as subjects were entered at index date.
Table 6-1. Description of study population
Coeliac disease cohort Control cohort
(n=4732) % (n=23620) %
Median observed time (years) 3.4 3.5
Total observed time (years) 18923 94323
Female 3095 65.4 18545 65.4
Age groups at entry to follow up (years)
0-3 196 4.1 985 4.2
>3-15 385 8.1 1915 8.1
>15-25 455 9.6 2270 9.6
>25-35 676 14.3 3375 14.3
>35-45 812 17.2 4045 17.1
>45-55 858 18.1 4285 18.1
>55-65 610 12.9 3050 12.9
>65-75 469 9.9 2342 9.9
>75 271 5.7 1353 5.7
6.4.1 Malignancy
Among people with coeliac disease 134 had at least one malignancy. The
overall rate of any malignancy for the coeliac disease cohort was 72·0 per
10000 person years compared to 55·9 per 10000 person years in the control
cohort (Table 6-2), giving approximately a 30% increase in the risk of any
malignancy among people with coeliac disease (HR 1·29 95% CI 1·06-1·55).
The absolute excess rate of any malignancy was 1·6 per 1000 person years. In
the analyses of specific malignancy subgroups I found an increase in the risk of
gastrointestinal cancer (HR 1·85) and lymphoproliferative disease (HR 4·80)
and decreases in the risk of both breast cancer (HR 0·35) and lung cancer (HR
0·34) in the coeliac disease group compared to the control population. When I
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restricted the analyses to the first year after diagnosis I found that most of the
hazard ratios were increased (any malignancy HR 1·97 (95% CI 1·39-2·80),
gastrointestinal malignancy HR 3·20 (95% CI 1·38-7·39)). After excluding
events within the first year of follow up after diagnosis the risks were, in general,
decreased (any malignancy HR 1·10 (95% CI 0·87-1·39), gastrointestinal
malignancy HR 1·56 (95% CI 0·95-2·58)). The absolute excess rate of any
malignancy in this period was 0·6 per 1000 person years.
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Table 6-2. Number of events, rates and hazard ratios for maligancy overall and resticted to before and after the first year of follow up after diagnosis
Analysis restricted to the first Analysis restricted to
Overall year of follow up after diagnosis follow up beyond one year after diagnosis
Number of Rate Hazard Number Rate Hazard Number Rate Hazard
N** events** (10000yr-1) ratio 95% CI of events** (10000yr-1) ratio 95%CI of events** (10000yr-1) ratio 95%CI
Any malignancy
Control cohort* 23433 519 55.9 1 111 52.7 1 395 56.5 1
Coeliac disease cohort 4695 134 72.0 1.29 (1.06-1.55) 44 104.2 1.97 (1.39-2.80) 87 62.2 1.10 (0.87-1.39)
Gastrointestinal cancer
Control cohort* 23605 81 8.6 1 14 6.6 1 64 9.0 1
Coeliac disease cohort 4724 30 15.9 1.85 (1.22-2.81) 9 21.1 3.20 (1.38-7.39) 20 14.1 1.56 (0.95-2.58)
Breast cancer
Control cohort* 23562 113 12.0 1 24 11.3 1 87 12.3 1
Coeliac disease cohort 4725 8 4.2 0.35 (0.17-0.72) 3 7.0 0.62 (0.19-2.06) 5 3.5 0.29 (0.12-0.70)
Lung cancer
Control cohort* 23616 58 6.2 1 14 6.6 1 43 6.0 1
Coeliac disease cohort 4728 4 2.1 0.34 (0.13-0.95) 1 2.3 0.36 (0.05-2.70) 3 2.1 0.35 (0.11-1.13)
Lymphoproliferative disease
Control cohort* 23612 24 2.5 1 6 2.8 1 17 2.4 1
Coeliac disease cohort 4724 23 12.2 4.80 (2.71-8.50) 11 25.8 9.12 (3.37-24.65) 12 8.4 3.55 (1.70-7.43)
Prostate cancer
Control cohort* 23614 30 3.2 1 4 1.9 1 25 3.5 1
Coeliac disease cohort 4730 6 3.2 0.99 (0.41-2.38) 1 2.3 1.24 (0.14-11.14) 5 3.5 1.00 (0.38-2.60)
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* baseline category, ** numbers vary as those individuals who had an event on the same date or before the start of follow-up were excluded
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6.4.2 Mortality
There were 237 deaths among people with coeliac disease and 902 in the
control cohort giving overall crude mortality rates of 125·3 per 10000 person
years and 95·7 per 10000 person years respectively (Table 6-3). These
rates corresponded to a hazard ratio of 1·31 (95% CI 1·13-1·51). The
absolute excess rate was 3·0 per 1000 person years. The risk in the first year
after diagnosis was considerably higher (HR 1·97 (95% CI 1·50-2·59))
compared to that subsequently (HR 1·17 (95% CI 0·98-1·38)). The absolute
excess rate when I excluded deaths within the first year of follow up after
diagnosis was 1·7 per 1000 person years. In the multivariate analyses, none
of the potential confounding factors I assessed altered the coefficients for the
coeliac disease by more than 10%, so they were not included in the final
models.
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Table 6-3. Number of deaths, rates and hazard ratios overall and restricted to before and after 1 year of follow up after diagnosis
Analysis restricted to the first Analysis restricted to
Overall year of follow up after diagnosis follow up beyond one year after diagnosis
Number of Rate Hazard Number Rate Hazard Number Rate Hazard
N** deaths** (10000yr-1) ratio 95% CI of deaths** (10000yr-1) ratio 95%CI of deaths** (10000yr-1) ratio 95%CI
Mortality
Control cohort* 23609 902 95.7 1 184 86.7 1 697 98.0 1
Coeliac disease cohort 4728 237 125.3 1.31 (1.13-1.51) 73 171.0 1.97 (1.50-2.59) 163 114.6 1.17 (0.98-1.38)
* baseline category
** numbers vary as those individuals who had an event on the same date or before the start of follow-up were excluded
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6.4.3 Incident/prevalent cases
When I stratified the analyses by prevalent/incident status, having excluded
events in the first year after diagnosis, the hazard ratios for overall
malignancy were 1·11 (95% CI 0·86-1·44) and 1·03 (95% CI 0·59-1·79)
respectively. For mortality the hazard ratio for the prevalent group was 1·09
(95% CI 0·90-1·33) and for the incident group 1·46 (95% CI 1·04-2·07).
6.4.4 Restriction analyses
When I repeated the analyses restricted to only those subjects with coeliac
disease who had had at least one gluten-free prescription I found no
important differences in the risk estimates (overall malignancy HR 1·20 (95%
CI 0·97-1·45), mortality HR 1·20 (95% CI 1·07-1·45)). When I restricted to
including only cases with two diagnostic codes for coeliac disease the overall
hazard ratios were marginally increased (overall malignancy HR 1.48 (95%
CI 1.10-2.00), mortality HR 1.66 (95% CI 1.35-2.05)).
6.4.5 Proportional hazard’s assumption
The log –log plots and plots of schoenfeld residuals against time are shown
for the overall malignancy analysis and the mortality analysis in Figure 6-1,
Figure 6-2, Figure 6-3 and Figure 6-4. The hazard decreases slightly over
time for both analyses. I dealt with this by splitting the follow up time into
before and subsequent to one year after diagnosis. In general, there was no
evidence against the proportional hazards assumption in any of the
presented models.
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Figure 6-1. Log -log plot for overall malignancy analysis
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Figure 6-2. Plot of schoenfeld residuals against time for the overall
malignancy analysis
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Figure 6-3. Log -log plots for the mortality analysis
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Figure 6-4. Plot of schoenfeld residuals for mortality analysis
-
.
2
-
8.
32
7e
-
17
.
2
.
4
.
6
.
8
Sc
ho
e
n
fe
ld
re
si
du
a
ls
0 5 10 15
Time
bandwidth = .8
Running mean smoother
131
6.4.6 Indirect standardisation analysis
The results of the indirect standardisation to the population of England and
Wales for both the coeliac and control cohort are shown in Table 6-4. The
control population are at substantially reduced risk of death compared to the
general population. The estimate of mortality risk is similar, if slightly
reduced, for the coeliac cohort compared with the cox proportional hazard’s
model described earlier.
Table 6-4. Indirect standardisation of both the coeliac disease and control
cohorts to the population of England and Wales
Observed Expected Standardised
Mortality Ratio
95% CI
Coeliac disease 223 177.88 1.25 1.09 1.43
Control population 848 924.62 0.92 0.86 0.98
6.4.7 Life table analysis
In the life table analysis (Table 6-5 and Table 6-6) the people with coeliac
disease overall have a roughly 2.8 year lower life expectancy than their
controls. With advancing age this difference diminishes so that by the age of
60 the life expectancy of a person with coeliac disease is only about 0.7
years lower than that of a control.
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Table 6-5. Life table for control cohort
Age group Deaths observed Years observed Mortality rate Qx Px lx dx Lx Tx ex
0 1 2694.5 0.0004 0.0019 0.9981 1000.0 1.9 4995.4 74991.5 75.0
5 0 4046.0 0.0000 0.0000 1.0000 998.1 0.0 4990.7 69996.1 70.1
10 0 3281.0 0.0000 0.0000 1.0000 998.1 0.0 4990.7 65005.4 65.1
15 1 3028.5 0.0003 0.0016 0.9984 998.1 1.6 4986.6 60014.6 60.1
20 3 4492.7 0.0007 0.0033 0.9967 996.5 3.3 4974.2 55028.0 55.2
25 6 5540.5 0.0011 0.0054 0.9946 993.2 5.4 4952.5 50053.8 50.4
30 4 6413.7 0.0006 0.0031 0.9969 987.8 3.1 4931.4 45101.3 45.7
35 1 7339.2 0.0001 0.0007 0.9993 984.7 0.7 4922.0 40169.9 40.8
40 15 7728.2 0.0019 0.0097 0.9903 984.1 9.5 4896.6 35247.9 35.8
45 20 9230.7 0.0022 0.0108 0.9892 974.6 10.5 4846.6 30351.3 31.1
50 28 9378.4 0.0030 0.0148 0.9852 964.1 14.3 4784.6 25504.8 26.5
55 42 8070.0 0.0052 0.0257 0.9743 949.8 24.4 4687.9 20720.2 21.8
60 70 6390.7 0.0110 0.0533 0.9467 925.4 49.3 4503.6 16032.3 17.3
65 93 5413.6 0.0172 0.0824 0.9176 876.1 72.1 4199.9 11528.7 13.2
70 142 4726.3 0.0300 0.1397 0.8603 803.9 112.3 3738.7 7328.8 9.1
75 186 3581.9 0.0519 0.2298 0.7702 691.6 158.9 3060.6 3590.1 5.2
80 290 2921.3 0.0993 0.3977 0.6023 532.6 211.8 529.5 529.5 1.0
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Table 6-6. LIfe table for coeliac disease cohort
Age group Deaths observed Years observed Mortality rate Qx Px lx dx Lx Tx ex
0 1 544.1 0.0018 0.0091 0.9909 1000.0 9.1 4977.1 72195.6 72.2
5 0 795.3 0.0000 0.0000 1.0000 990.9 0.0 4954.3 67218.5 67.8
10 0 664.9 0.0000 0.0000 1.0000 990.9 0.0 4954.3 62264.2 62.8
15 0 605.1 0.0000 0.0000 1.0000 990.9 0.0 4954.3 57310.0 57.8
20 1 870.7 0.0011 0.0057 0.9943 990.9 5.7 4940.1 52355.7 52.8
25 0 1120.0 0.0000 0.0000 1.0000 985.2 0.0 4925.9 47415.6 48.1
30 2 1284.8 0.0016 0.0078 0.9922 985.2 7.6 4906.8 42489.7 43.1
35 2 1495.9 0.0013 0.0067 0.9933 977.5 6.5 4871.4 37582.9 38.4
40 8 1550.8 0.0052 0.0255 0.9745 971.0 24.7 4793.3 32711.5 33.7
45 6 1895.0 0.0032 0.0157 0.9843 946.3 14.9 4694.3 27918.2 29.5
50 12 1924.8 0.0062 0.0307 0.9693 931.4 28.6 4585.7 23223.8 24.9
55 16 1631.9 0.0098 0.0478 0.9522 902.8 43.2 4406.2 18638.1 20.6
60 17 1293.7 0.0131 0.0636 0.9364 859.6 54.7 4161.5 14231.9 16.6
65 28 1053.9 0.0266 0.1246 0.8754 805.0 100.3 3774.1 10070.4 12.5
70 35 890.2 0.0393 0.1790 0.8210 704.7 126.1 3208.1 6296.2 8.9
75 38 723.8 0.0525 0.2320 0.7680 578.6 134.3 2557.2 3088.1 5.3
80 71 565.2 0.1256 0.4780 0.5220 444.3 212.4 530.9 530.9 1.2
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6.5 Discussion
6.5.1 Principal findings
The results of the study show that people with coeliac disease have modest
increases in the risks of malignancy and mortality compared to the general
population. In addition the life table analysis shows that when compared to
the general population people with coeliac disease have a life expectancy
reduced on average by 2.8 years. The increased risks were most apparent in
the first year after diagnosis and the decreased risks thereafter suggest that
some of the overall excess risk is likely to be due to ascertainment. I also
found that people with coeliac disease were at approximately a third of the
risk of breast or lung cancer compared to the general population in contrast
to their increase in risk of gastrointestinal and lymphoproliferative
malignancy.
6.5.2 Limitations and merits
A potential weakness of epidemiological studies using routinely collected
data such as the GPRD is the validity of diagnostic data for each individual
subject involved, particularly with respect to histological status. As discussed
before there have been many validation studies of the diagnostic accuracy of
the GPRD. Specifically this has included cancer diagnoses which have been
found to be accurate [137, 138, 144, 154]. Furthermore, I have carried out
my own validation of the diagnosis of coeliac disease (section 3.7.9) and
when I restricted the analyses to those people with coeliac disease who also
had at least one gluten free prescription, to increase the specificity of the
coeliac disease diagnosis, there were no substantial changes in the effect
estimates. Although the relative risks were marginally greater in the analysis
restricted to those cases with two codes, this is not unexpected as it is likely
to include those with most severe disease.
Death recording has also not been specifically validated in the GPRD and
the findings of the indirect standardisation suggest that it is possible that
death has been under recorded in the control population. An alternative
explanation for the low SMR of the control population is that the GPRD
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contains a population sample of England and Wales that is not wholly
representative of the entire population to the extent that it is, on average, at
less risk of death. If this is true then it would appear more appropriate to use
the internal comparison as presented in the cox proportional hazard’s model.
As discussed before people with coeliac disease may attend general
practitioners more frequently than the general population (section 3.4.10)
and therefore there is the possibility of differences in ascertainment of some
malignancies such as breast or prostate cancer as a result of opportunistic or
systematic screening. In addition when people are first investigated for
coeliac disease the likelihood of detecting an occult or overt malignancy may
be increased or else coeliac disease may be more likely to be detected
during the investigation of cancer. If this potential ascertainment bias exists
then it would suggest that the risks of lung and breast cancer in the study are
underestimates of any reduction through more complete ascertainment
among people with coeliac disease. In contrast, the excess risk of
gastrointestinal malignancy is likely, in part, to be contributed to by the more
detailed investigation of gastrointestinal symptoms particularly at
presentation. Unlike previous studies, I had some ability to assess the
impact of potential confounders such as body mass index and smoking
status on both malignancy and mortality risk. Notwithstanding the
incomplete data for these variables I found no suggestion of confounding.
6.5.3 Comparision with other studies
The findings with respect to the risks of overall malignancy and mortality
suggest much more modest increases in comparison to other studies. The
most recent of these, from Sweden, found slightly greater risks of both
malignancy (SIR 1·3) and mortality (SMR 2·0) compared to mine[123, 124].
The slightly greater risks they estimated may reflect greater severity of
disease at presentation and/or a period effect as all their subjects with
coeliac disease had been hospitalised at least once and follow up ended at
least 6 years earlier than in the study. The majority of other studies have
found overall increased risks for malignancy or mortality of 2-fold or
greater[118, 119, 121, 122]. These studies have been in cohorts of people
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with coeliac disease diagnosed and followed up some time ago, or from
specialist referral centres. Generally they have been limited by not being
population based or too small to provide robust estimates.
My analysis using the life table methodology has not been reported before
for coeliac disease. Its advantage over the presentation of hazard ratios is
that from the tables I can estimate the life expectancy of the people with
coeliac disease compared to the control group at different ages.
Notwithstanding the two main assumptions in constructing a life table i.e. that
there has been no secular change in survivorship over calendar time and
that those censored are assumed to have the same survival experience as
those followed up, the findings indicate only a small decrease in life
expectancy.
The finding of a marked reduction in the incidence of breast cancer among
people with coeliac disease is consistent with two previous studies[121, 124].
A lack of breast cancer in people with coeliac disease was observed in both
the Lothian and Swedish cohorts yet the former study was too small to be
sure of the association and Askling et al were concerned that, among many
comparisons, it may have been a chance finding. It is most unlikely that
socio-economic status is an important confounder in this relationship as
breast cancer has been consistently shown to be associated with higher
socio-economic groups, and there is no good evidence that people with
diagnosed coeliac disease are of lower socio-economic status[155]. I have
recently shown that people with undetected coeliac disease have low serum
lipids and as both this measurable physiological characteristic and dietary fat
intake have been implicated in the aetiology of breast cancer, studying the
mechanism of protection in coeliac disease may give an opportunity to clarify
their role in its aetiology[149, 156-158].
As the study is the first to report a significant reduction in lung cancer
incidence this finding must be treated with caution, indeed whether this is a
causal relation remains unclear. People with coeliac disease appear to
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smoke less than the general population, even when “undiagnosed”[40, 41,
149]. While smoking habit was included in the multivariate analysis some
data were missing and I was unable to assess past smoking accurately.
Indeed, although adjusting for smoking status did not substantially change
the results residual confounding remains a possibility. Nonetheless there
has been speculation that factors other than smoking, such as nutritional
status and dietary intake of carotinoids, are important in the causation of lung
neoplasms[159].
6.5.4 Summary
The findings show that people with diagnosed coeliac disease have modest
increases in the relative and absolute risk of malignancy and mortality, with
life expectancy reduced on average only by 2.8 years. Most of the excess
risk occurs in the first year after diagnosis and although there are markedly
increased risks of some malignancies such as gastrointestinal cancers and
lymphoma there are substantial reductions in the risk of other, common,
cancers such as those of the lung and breast. The latter findings are of
particular interest with respect to the possible genetic, nutritional or other
environmental factors that may protect people with coeliac disease against
developing certain malignancies. Indeed by understanding the mechanism
of protection against breast cancer in people with coeliac disease we may
gain insight into its aetiology.
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7 Conclusions
7.1 Principal findings
The principal findings of this thesis are that:
x Undetected coeliac disease is likely to affect about 1% of the
population of England aged 45-76.
x Those affected by undetected coeliac disease have an increased
risk of osteoporosis and mild anaemia but also have a
favourable cardiovascular risk profile, compared to those without
evidence of the disease.
x In people with clinically diagnosed coeliac disease, compared to
the general population, there are small increases in both the
absolute and relative overall risk of fracture with about a 2-fold
increase in the risk of hip fracture.
x Adults with treated coeliac disease have a favourable vascular
disease risk factor profile but numbers having heart attacks or
strokes are modest and rates of heart attack and stroke are not
reduced.
x There are modest increases in the overall risks of malignancy
and mortality in people with coeliac disease and most of this
excess risk occurred in the first year of follow up after diagnosis.
x There is a marked reduction in the risk of breast and lung cancer
in people with coeliac disease.
7.2 Interpretation
The findings of this thesis suggest that the impact on health of both
undetected coeliac disease and clinically diagnosed coeliac disease is
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important. Although there are clearly some negative health effects, for
example mild anaemia and osteoporosis, the possible benefits of
having undetected coeliac disease have yet to be fully clarified. The
implications on risk of cardiovascular disease of lower body mass
index, lower blood pressure, and lower serum cholesterol are potentially
large, and as yet, unresolved. From an individual perspective, people
with clinically diagnosed, treated, coeliac disease now have information
to inform them of the, reasonably precise, actual risks to their health in
terms of a range of morbidities and life expectancy. From a population
perspective, the suggestion of identifying as many people as possible
with the disease through either mass screening or targeted case finding
is, in my view, not supported.
7.3 Recommendations for future work
7.3.1 Undetected coeliac disease
Further approaches to clarify the impact of both undetected and
clinically diagnosed coeliac disease are suggested by this work. Firstly
the cohort described in section 1 has continued follow-up for cause-
specific mortality. In the future, a survival analysis carried out on this
cohort would give information about the mortality risk in those people
with serological evidence of coeliac disease compared to those without
evidence of the disease. This plan has the disadvantage of being
dependent on a great deal more follow-up before a meaningful analysis
could be undertaken. An alternative approach would be to identify a
separate cohort that has both serum available for serological testing
and prospective follow up for both mortality and perhaps other
outcomes (for example malignancy) that has already accrued enough
person time and events to give precise estimates.
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7.3.2 Diagnosed coeliac disease
Further work that has been recently completed using the GPRD data in
this thesis includes the fertility experience of women with coeliac
disease compared to the general population. The impact of
contemporary clinically diagnosed disease could be further assessed
using a similar historical cohort using a larger database similar to the
GPRD. Such databases may be available in the future. This would
allow an extension of the methodology I have used where comparisons
of the risk of various outcomes are assessed before and after
diagnosis.
7.3.3 Breast and lung cancer aetiology
The findings in relation to both breast and lung cancer are intriguing.
Other study designs to address the apparent “protective” effect of
coeliac disease may be of help. For example nested case-control
studies from cohorts designed for follow up of cancer may give enough
power to look at coeliac disease as an exposure, and in addition be
able to explore the way other environmental exposures and
physiological measures interact.
7.3.4 Cholesterol and other risk factors for cardiovascular disease
The findings of this thesis appear to be consistent in relation to
cholesterol and blood pressure. That cholesterol could change after
treatment is a distinct possibility however it is possible that early life
factors that determine lifetime cholesterol levels may override any effect
of gluten exclusion. As an initial step measurement of cholesterol and
other physiological markers could be carried out before and after
introduction of a gluten free diet in newly diagnosed people with coeliac
disease. If data were available in such people of early life factors such
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as birth weight and in utero exposures then our understanding of the
mechanisms of cardiovascular disease could be greatly enhanced.
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